Use these links to rapidly review the document
Table of ContentsUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐
Preliminary Proxy Statement
☐
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒
Definitive Proxy Statement
☐
Definitive Additional Materials
☐
Soliciting Material under §240.14a-12
REPLIMUNE GROUP, INC.
| | |
Filed by the Registrantý |
Filed by a Party other than the Registranto |
Check the appropriate box: |
o |
|
Preliminary Proxy Statement |
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
ý |
|
Definitive Proxy Statement |
o |
|
Definitive Additional Materials |
o |
|
Soliciting Material under §240.14a-12
|
(Name of Registrant as Specified In Its Charter)
| | | | |
REPLIMUNE GROUP, INC. |
(Name of Registrant as Specified In Its Charter) |
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
Payment of Filing Fee (Check the appropriate box): |
ý |
|
No fee required. |
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| | (1) | | Title of each class of securities to which transaction applies:
|
| | (2) | | Aggregate number of securities to which transaction applies:
|
| | (3) | | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
| | (4) | | Proposed maximum aggregate value of transaction:
|
| | (5) | | Total fee paid:
|
o |
|
Fee paid previously with preliminary materials. |
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|
|
(1) |
|
Amount Previously Paid:
|
| | (2) | | Form, Schedule or Registration Statement No.:
|
| | (3) | | Filing Party:
|
| | (4) | | Date Filed:
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)Payment of Filing Fee (Check the appropriate box):
☒
No fee required.
☐
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
(2)
Aggregate number of securities to which transaction applies:
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
Proposed maximum aggregate value of transaction:
(5)
Total fee paid:
☐
Fee paid previously with preliminary materials.
☐
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
(2)
Form, Schedule or Registration Statement No.:
(3)
Filing Party:
(4)
Date Filed:
500 Unicorn ParkWoburn, MA 01801 Dear
Stockholder:Fellow Stockholders:
On behalf of the Board of Directors of Replimune Group, Inc. (the
"Company", "we"“Company,” “we” or
"Replimune"“Replimune”), I invite you to attend our
20192021 Annual Meeting of Stockholders (the
"2019 Annual Meeting"“Annual Meeting”)
. The 2019 Annual Meeting, which will be held on Wednesday, September
4, 2019,8, 2021, at 2:00 p.m., Eastern
Time,Time. The Annual Meeting will be a completely virtual meeting of stockholders conducted via live webcast. You will be able to participate in the Annual Meeting, vote online during the Annual Meeting and submit your questions during the Annual Meeting by visiting meetings.computershare.com/MACDYTJ, but you will not be able to attend the Annual Meeting in person. A Notice of Internet Availability of Proxy Materials, which contains instructions on how to access online the proxy statement accompanying this letter (the “Proxy Statement”) and our Annual Report for the fiscal year ended March 31, 2021 is first being sent to stockholders on or about July 26, 2021. We urge you to carefully read our proxy materials, which provide important information about the Annual Meeting and will serve as your guide to the business that will be conducted at the
offices of Morgan, Lewis & Bockius LLP, One Federal Street, Boston, Massachusetts 02110.Annual Meeting.
The matters to be voted upon at the
2019 Annual Meeting are listed in the Notice of
2019 Annual Meeting and more fully described in the
proxy statement accompanying this letter (the "Proxy Statement"). We know that manyProxy Statement.
All holders of record of our
Company's stockholders (each, a "Stockholder",common stock at the close of business on July 15, 2021, the record date, are entitled to notice of and
collectively,to vote at the
"Stockholders") will be unable to attend the 2019 Annual Meeting
and any continuation, postponement, or adjournment thereof. Whether or not you participate in
person.the Annual Meeting, it is important that your shares be represented and voted during the meeting. We therefore are soliciting proxies so that each
Stockholderstockholder has an opportunity to vote on the matters that are scheduled to come before the
Stockholdersstockholders at the
2019 Annual Meeting.
You mayIf you have previously received our Notice of Internet Availability of Proxy Materials (the “Internet Notice”), then instructions regarding how you can vote
over the Internet, by telephone, or by signing, dating and returning yourare contained therein. If you have received a proxy card,
promptly inthen instructions regarding how you can vote are contained on the
enclosed postage-paid envelope.proxy card. Submitting your vote via the Internet or by telephone or proxy card will not affect your right to vote
in personelectronically if you decide to
virtually attend the
2019 Annual Meeting. You may revoke your proxy at any time prior to the time it is voted at the 2019 Annual Meeting. If your shares are held in street name (held for your account by a broker or other nominee), you will receive instructions from your broker or other nominee explaining how to vote your
shares. Whether or not you expect to attend the Annual Meeting electronically, we urge you to vote your shares
as promptly as possible to ensure your representation and
you will have the
option to cast your vote by telephone or overpresence of a quorum at the
Internet if your voting instruction form from your broker or nominee includes instructions and a telephone number or Internet website to do so. Regardless of the number of shares you own, your presence in person or by proxy is important for quorum purposes and your vote is important for proper corporate action.Annual Meeting.
Thank you for your continuing interest in the Company.
We look forward to seeing you at the 2019 Annual Meeting.| | | | | Sincerely, | |
| | | Sincerely, |
|
|
/s/ ROBERT COFFIN
Robert Coffin, Ph.D.
President and Philip Astley-SparkePhilip Astley-Sparke
Chief Executive Officer |
July 22, 2021 | | August 9, 2019 |
500 Unicorn ParkWoburn, MA 01801 NOTICE OF 20192021 ANNUAL MEETING OF STOCKHOLDERS The
20192021 Annual Meeting of Stockholders (the
"2019 Annual Meeting"“Annual Meeting”) of Replimune Group, Inc. (the
"Company", "we"“Company,” “we” or
"Replimune"“Replimune”) will be held on Wednesday, September
4, 2019,8, 2021, at 2:00 p.m., Eastern
Time, atTime. We have adopted a virtual format for our Annual Meeting, which will be conducted via live webcast. You will be able to attend the
officesAnnual Meeting online and submit your questions during the meeting by visiting meetings.computershare.com/MACDYTJ and entering your 15-digit control number included in your Notice of
Morgan, Lewis & Bockius LLP, One Federal Street, Boston, Massachusetts 02110Internet Availability of Proxy Materials (the “Internet Notice”), on any proxy card you received or on the instructions that accompanied your proxy materials. The Annual Meeting will be held for the purpose of considering
threethe following company-sponsored proposals:
1.
To elect Philip Astley-Sparke, Kapil Dhingra,Robert Coffin, Hyam Levitsky and Joseph SlatteryDieter Weinand as Class IIII members of the Company'sReplimune’s Board of Directors (each a "Class I director"“Class III director”), each to serve for a three-year term until the Company's 2022Replimune’s 2024 Annual Meeting of Stockholders and until theirhis respective successors aresuccessor is duly elected and qualified; and
2.
2.To amend the Company's certificate of incorporation to remove the exclusive federal forum clause and make certain amendments to the exclusive Delaware forum clause; and
3.To ratify the
appointmentselection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for
the CompanyReplimune for the fiscal year ending March 31,
2020.2022.
We will also consider and act upon any other matters that properly come before the
2019 Annual Meeting or any
continuation, adjournment or postponement thereof.
Our Board of Directors recommends that you vote "“FOR"” each of the nominees for Class IIII director (Proposal No. 1); " and “FOR" the amendment of the Company's certificate of incorporation (Proposal No. 2); and "FOR"” ratification of the proposedselection of PricewaterhouseCoopers LLP as the independent registered public accounting firm (Proposal No. 3)2). Our Board of Directors has fixed the close of business on July
17, 201915, 2021 as the record date for determining stockholders entitled to notice of and to vote at the
2019 Annual Meeting. Therefore, each outstanding share of
Replimune'sour common stock
(Nasdaq: REPL) entitles the holder of record of such shares at the close of business on July
17, 201915, 2021 to receive notice of, and to vote at, the
2019 Annual Meeting or any
continuation, adjournment or postponement
thereof. A list of
stockholders entitled to vote at the
2019Annual Meeting will be available for examination during ordinary business hours for 10 days prior to the Annual Meeting at our principal executive offices at 500 Unicorn Park, Woburn, MA 01801. This stockholder list will also be available for review online during the Annual Meeting.
All stockholders as of To participate in the record date,Annual Meeting, including to vote via the Internet or their duly appointed proxies, may attend the meeting. If you attend,telephone, you will be asked to present valid picture identification such as a driver's licenseneed the 15-digit control number included in your Internet Notice, on any proxy card you received or passport. If your stock is held in a brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares held in street name, and this proxy statement is being forwarded to you by your broker or nominee. As a result, your name does not appear on our list of stockholders. If your stock is held in street name, in addition to picture identification, you should bring with you a letter or account statement showing that you were the beneficial owner of our stock on the record date, in order to be admitted to the meeting.
instructions that accompanied your proxy materials.
Whether or not you expect to attend the
meeting,Annual Meeting electronically, we urge you to vote your shares
by Internet, telephone, or by signing, datingas promptly as possible to ensure your representation and
returning the
proxy card included in these materials.presence of a quorum at the Annual Meeting. If you choose to attend the
2019 Annual Meeting
electronically, you may still vote your shares
in person,electronically at the Annual Meeting, even if you have previously voted or returned your proxy by any of the methods described in our proxy statement. If your shares are held in street name in a bank or brokerage account, please refer to the materials provided by your bank, broker or other nominee for voting instructions.
Your proxy is revocable in accordance with the procedures set forth in our proxy statement.
All stockholders are extended a cordial invitation to attend the
meeting.Annual Meeting via live webcast.
| | | |
| |
|
|---|
| | | By Order of the Board of Directors, | |
|
|
| | /s/ ROBERT COFFIN
Robert Coffin, Ph.D.
President and Philip Astley-SparkePhilip Astley-Sparke
Chief Executive Officer
August 9, 2019July 22, 2021 | |
Table of Contents
TABLE OF CONTENTS
TABLE OF CONTENTS
| | | |
| | Page |
|---|
PROXY STATEMENT
| Page | 1 |
| | | | | 1 | | |
| | | | | 1 | | |
| | | | | | | |
| | | | | 68 | | |
Board Composition and Structure | | | | | 68 | | |
| | | | | 79 | | |
| | | | | 1113 | | |
| | | | | 1113 | | |
Board Meetings, Attendance and Executive Sessions | | | | | 1113 | | |
Board of Directors Leadership Structure | | | | | 1113 | | |
The Board of Directors'Directors’ Role in Risk Oversight | | | | | 1214 | | |
| | | | | 1214 | | |
Polices Governing Director Nominations | | | | | 1416 | | |
Communication with the Board of Directors | | | | | 1517 | | |
Compensation Committee Interlocks and Insider Participation
| | 15 |
Code of Business Conduct and Ethics and Corporate Governance Guidelines | | | | | 1618 | | |
| | | | | 18 DIRECTOR COMPENSATION
| | 17 |
| | | | | 19 | | |
| | | | | 21 | | |
| | | | | 1921 | | |
| | | | | 2123 | | |
Summary Compensation Table | | | | | 2123 | | |
Outstanding Equity Awards at Fiscal Year-End | | | | | 2324 | | |
| | | | | 2325 | | |
| | | | | 2426 | | |
| | | | | 2627 | | |
| | | | | 2728 | | |
PROPOSAL NO. 2—AMENDMENT OF CERTIFICATE OF INCORPORATION | | 28 |
PROPOSAL NO. 3—2 — RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
| | | | | | | |
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm | | | | | 29 | | |
Principal Accountant Fees and Services | | | | | 29 | | |
BENEFICIAL OWNERSHIP OF COMMON STOCK | | | | | 31 | | |
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS | | | | | 35 | | |
Related Party Transactions Policy | | | | | 35 | | |
| | | | | 36 | | |
| | 37 |
Availability of Certain Documents | | | | | 3736 | | |
Stockholders Sharing an Address / Household Householding | | | | | 3736 | | |
Stockholder Proposals and Nominations | | | | | 3736 | | |
| | | | | 3837 | | |
Replimune Group, Inc.
500 Unicorn Park18 Commerce Way
Woburn, MA 01801
PROXY STATEMENT FOR 20192021 ANNUAL MEETING OF STOCKHOLDERS
To Be Held On Wednesday, September 4, 2019 at8, 2021 At 2:00 p.m. Eastern Time
At the offices of Morgan, Lewis & Bockius LLP,
At One Federal Street, Boston, Massachusetts 02110
This proxy statement (“Proxy Statement”) is furnished in connection with the solicitation by the Board of Directors (the “Board”) of Replimune Group, Inc., a Delaware corporation (“Replimune,” “we,” “our,” “us,” or the “Company”), of proxies in the accompanying form to be used at our 2021 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 8, 2021 at 2:00 p.m., Eastern Time, and any continuation, postponement or adjournment thereof. We have adopted a virtual format for our Annual Meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting meetings.computershare.com/MACDYTJ and entering your 15-digit control number included in your Notice of Internet Availability of Proxy Materials (the “Internet Notice”), on any proxy card you received or on the instructions that accompanied your proxy materials.
The Board has fixed the record date for determining those stockholders entitled to notice of, and to vote at, the Annual Meeting as of the close of business on July 15, 2021 (the “Record Date”).
When are this proxy statementProxy Statement and the accompanying materials scheduled to be sent to stockholders?
This Proxy Statement and Replimune’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021 (the “Annual Report”) will be released to those stockholders as of the Record Date on or about July 26, 2021.
Notice of Internet Availability of Proxy Materials.
As permitted by Securities and Exchange Commission (“SEC”) rules, Replimune is making this Proxy Statement and its Annual Report available to its stockholders electronically via the Internet. On or about July 26, 2021, we will begin mailing a notice, which we refer to herein as the Internet Notice, to our stockholders as of the Record Date containing instructions on how to access this Proxy Statement and our Annual Report and the mechanisms by which such stockholders may vote. You may then access these proxy
statement and accompanying proxy card,materials online or
for shares held in street name (held for your account byyou may request that a
broker or other nominee), voting instruction form, are scheduled toprinted copy of the materials be
first sent to
stockholders beginning on August 14, 2019. Who is soliciting my vote?
The Boardyou. If you choose to receive a paper or e-mail copy of Directors (the "Board") ofthese proxy materials, you must request such by telephone by calling 1-866-641-4276, online at www.envisionreports.com/REPL or by e-mail to investorvote@computershare.com with “Proxy Materials Replimune Group, Inc. (the "Company", "we" or "Replimune")” in the subject line, in each case, before August 25, 2021. There is solicitingno charge to you for requesting a copy of these proxy materials.
The Internet Notice instructs you on how to access and review all of the important information contained in the Proxy Statement and Annual Report. The Internet Notice also instructs you on how you may submit your proxy over the Internet.
Who can vote forat the proposalsAnnual Meeting?
You are entitled to
be voted onvote at
our 2019the Annual Meeting
only if you were a stockholder of
Stockholders (the "2019 Annual Meeting"). When isrecord at the record dateclose of business on the Record Date, or if you hold a valid proxy for the Annual Meeting?
Replimune's Board has fixed the record date for the 2019 Annual Meeting asMeeting. As of the close of business on July 17, 2019 for determining stockholders entitled to notice of and to vote at the 2019 Annual Meeting.
How many votes can be cast by all stockholders?
A total of 31,666,182Record Date, we had 46,730,451 shares of common stock of Replimune were outstanding on July 17, 2019 and are entitled to be voted at the 2019 Annual Meeting.outstanding. Each share of common stock is entitledentitles the holder to one vote on each matter presented at the 2019 Annual Meeting. There is no cumulative voting.
Who can attend and participate in the Annual Meeting?
You may attend and participate in the Annual Meeting online only if you were a stockholder as of the Record Date, or if you hold a valid proxy for the Annual Meeting. We have adopted a virtual format for our
Annual Meeting. There will not be a physical meeting location and you will not be able to attend the Annual Meeting in person. We have designed the format of this year’s virtual Annual Meeting to ensure that our stockholders who attend the Annual Meeting online will be afforded the same rights and opportunities to participate as they would at an in-person meeting. You will be able to attend the Annual Meeting online, vote your shares online during the Annual Meeting and submit questions online during the Annual Meeting by visiting meetings.computershare.com/MACDYTJ. To attend and participate in the Annual Meeting, you will need the 15-digit control number included in your Internet Notice, on any proxy card you received or on the instructions that accompanied your proxy materials. If you lose your 15-digit control number, you may join the Annual Meeting as a “Guest” but you will not be able to vote, ask questions or access the list of stockholders as of the Record Date.
If your shares are held in “street name,” as described below, you must register in advance to attend the Annual Meeting online using the instructions found under the caption “How do I vote?” below. You will need to obtain your own Internet access if you choose to attend the Annual Meeting online and/or vote over the Internet.
The Annual Meeting webcast will begin promptly at 2:00 p.m., Eastern Time. We encourage you to access the Annual Meeting prior to the start time, leaving ample time for check-in procedures.
What is the difference between a stockholder of record and beneficial owner of shares held in “street name”?
Stockholder of Record. If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A. (“Computershare”), you are considered the stockholder of record with respect to those shares, and the Internet Notice, or if requested, these proxy materials, will be sent directly to you by Replimune.
Beneficial Owner of Shares Held in “Street Name.” If your shares are held in an account at a brokerage firm, bank, broker-dealer, or other similar organization, then you are the beneficial owner of shares held in “street name,” and the Internet Notice, or if requested, these proxy materials will be forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct that organization on how to vote the shares held in your account.
If you are a stockholder of record and your shares are registered directly in your name, you may vote:
•
By Internet. You may vote by proxy via the Internet at www.investorvote.com/www.envisionreports.com/REPL by following the instructions provided on the Internet Notice or any proxy card.card you received. In order submit a vote over the Internet, you must have your 15-digit control number included in your Internet Notice or on any proxy card you received.
•
•By Telephone. If you live in the United States or Canada, you may vote by proxy by calling toll-free 1-800-652-VOTE (8683) and by following the instructions provided on the Internet Notice or any proxy card. Youcard you received. In order to submit your vote over the telephone, you must have theyour 15-digit control number that is included in your Internet Notice or on theany proxy card when voting.you received.
•
•By Mail. Complete and mail yourany proxy card you may have received in the accompanying postage prepaid envelope you receive, and return the proxy card to Computershare Proxy Services, C/O Computershare Investor Services, P.O. Box 505000,505008, Louisville, KY 40233.40233-9814. Your proxy will be voted in accordance with your instructions. If you have received printed copies of these proxy materials and sign and return the enclosed proxy but do not otherwise specify how you want your shares voted, they will be voted "“FOR"” the election of the Class IIII director nominees named herein to the Board "and “FOR"” the amendmentratification of our certificate of incorporation; and "FOR" the ratificationselection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2020,2022, and will be voted according to the discretion of the proxy holder
Table of Contents
•
In PersonElectronically at the Annual Meeting. If you attend the meeting online via live webcast, you must bring a form of picture identification with you. You may deliverwill need the 15-digit control number included in your completedInternet Notice, on any proxy card in person,you received or
on the instructions that accompanied your proxy materials to vote electronically during the meeting. If you lose your 15-digit control number, you may
join the Annual Meeting as a “Guest” but you will not be able to vote,
by completing a ballot, which will be available atask questions or access the
meeting.list of stockholders as of the Record Date.
If your shares are held in street name (held for your account by a broker or other nominee), you may vote:
•
By Internet or By Telephone. You will receive instructions from your broker or other nominee if you are permitted to vote by Internet or telephone.
•
•By Mail. You will receive instructions from your broker or other nominee explaining how to vote your shares.
•
•In Person atRegister to Attend the Annual Meeting. If youYou may register to attend the meeting online via webcast as a stockholder in additionadvance (allowing you to picture identification,both vote and ask questions during the Annual Meeting). To register to attend the Annual Meeting online, you must submit proof of your proxy power (legal proxy) reflecting your holdings in the Company along with your name and email address to Computershare. Requests for registration must be labeled as “Legal Proxy” and be received no later than 5:00 p.m., Eastern Time, on September 7, 2021. You will receive a confirmation of your registration by email after Computershare receives your registration materials. Requests for registration should bring bothbe directed to Computershare in the following manner: (1) by email: Forward the email from your broker, or attach an account statementimage of your legal proxy, to legalproxy@computershare.com; or (2) by mail: Computershare, Replimune Group, Inc. Legal Proxy, P.O. Box 43001, Providence, RI 02940-3001.
•
Attend the Annual Meeting Using a letter fromControl Number. We expect that the record holder indicating that you ownedvast majority of beneficial holders will be able to attend and participate in the shares asAnnual Meeting by logging into the Annual Meeting using the control number received with the voting instruction form provided by your broker or other nominee. However, some beneficial holders may need to request a legal proxy and register in advance of the record date,andAnnual Meeting pursuant to the instructions above under “Register to Attend the Annual Meeting in Advance.” Please contact theyour broker or other nominee who holdsto confirm whether your sharescontrol number will allow you to access the Annual Meeting or whether you will need to obtain a broker'slegal proxy card and bring it with you to the meeting.register in advance.
What are the Board'sBoard’s recommendations on how to vote my shares?
The Board recommends a vote:
•
Proposal No. 1: "“FOR"” the election of each of Philip Astley-Sparke, Kapil Dhingra,Robert Coffin, Hyam Levitsky and Joseph SlatteryDieter Weinand as Class IIII members of the Board (the "Class I directors"“Class III directors”).
•
•Proposal No. 2: "“FOR" amendment” ratification of the Company's certificate of incorporation to remove the exclusive federal forum clause and make certain amendments to the exclusive Delaware forum clause.
•Proposal 3: "FOR" ratificationselection of PricewaterhouseCoopers LLP as Replimune'sReplimune’s independent registered public accounting firm for the fiscal year ending March 31, 2020.2022.
Who pays the cost for soliciting proxies?
Replimune will bear the cost of solicitation of proxies. This includes the charges and expenses of brokerage firms and others for forwarding solicitation material to beneficial owners of our outstanding common stock. Replimune may solicit proxies by mail, personal interview, telephone or via the Internet through its officers, directors and other management employees, who will receive no additional compensation for their services.
We may also request that brokers, nominees, custodians and other fiduciaries forward soliciting materials to the beneficial owners of shares held by the brokers, nominees, custodians and other fiduciaries. We will reimburse these persons for their reasonable expenses in connection with these activities.
Pursuant to rules adopted by the SEC, we have elected to deliver the Internet Notice to stockholders and provide Internet access to our proxy materials. Stockholders may obtain paper copies of the proxy materials free of charge by following the instructions provided in the Internet Notice.
Can I change or revoke my vote?
You may revoke your proxy at any time before it is voted by notifyingdelivering written notice to our Investor Relations at Replimune in writingteam at our principal executive offices, by returning a signed proxy with a later date, by transmitting
a subsequent vote over the Internet or by telephone prior to the close of the Internet voting facility or the telephone voting facility, or by attending the
meetingAnnual Meeting and voting
in person.electronically. If your stock is held in street name, you must contact your broker or nominee for instructions as to how to change or revoke your vote.
The presence
in person or by proxy, of holders of at least a majority of the issued and outstanding shares entitled to vote is necessary to constitute a quorum for the transaction of business at the
2019 Annual Meeting.
Abstentions and "broker non-votes," if any, will be counted as present and entitled to
Table of Contents
vote forFor purposes of determining whether a quorum isexists, we count as present forany shares that are voted over the transactionInternet, by telephone or by completion and submission of businessa proxy or that are represented virtually at the 2019 Annual Meeting.
"Broker non-votes" Further, for purposes of establishing a quorum, we will count as present shares that a stockholder holds even if the stockholder votes to withhold or abstain or votes on only one of the proposals. In addition, we will count as present shares held in street name by brokers or other nominees that indicate on their proxies that they do not have authority to vote those shares on Proposal No. 1. If a quorum is not present, we expect to adjourn the Annual Meeting until we obtain a quorum.
What are broker non-votes?
“Broker non-votes” are shares represented at the
2019 Annual Meeting held by brokers, banks or other nominees (i.e., in
"street name"“street name”) which do not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner. Generally, nominees may vote to ratify the selection of independent auditors
and on other "discretionary" or "routine" items.(Proposal No. 2). In contrast, nominees may not vote to elect directors
(Proposal No. 1), because
those proposals arethat proposal is considered
"non-discretionary" items.a “non-discretionary” item. Accordingly, if you do not instruct your broker, bank or other nominee how to vote your shares on
"non-discretionary" matters,Proposal No. 1, your broker, bank or other nominee will not be permitted to vote your shares on
these matters.this matter. This is a
"broker“broker non-vote.
"”
What vote is required to approve each item?
Required Vote—Vote — Election of Directors (Proposal No. 1). Directors will be elected by a plurality of the votes cast in personelectronically or represented by proxy at the 2019 Annual Meeting and entitled to vote on the election of directors. This means that the three individuals receiving the highest number of "FOR"“FOR” votes will be elected as directors. Votes that are withheld and broker non-votes will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the election. Required Vote—Amendment of our certificate of incorporation (Proposal No. 2). The affirmative vote of at least seventy-five percent (75%) of the outstanding shares of our capital stock present in person or represented by proxy at the 2019 Annual Meeting and entitled to vote is required to approve the amendment of our certificate of incorporation. An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote "against" the amendment of our certificate of incorporation. Broker non-votes will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the proposal. Required Vote—Vote — Ratification of the Selection of Independent Registered Public Accounting Firm (Proposal No. 3)2). The affirmative vote of a majority of shares of our common stock present in person or represented by proxy at the 2019 Annual Meeting and entitled to vote is required to ratify the selection of our independent auditors. An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote "against"“against” ratification of the independent auditors. Because the ratification of the independent auditors is a routine matter, a nominee holding shares in street name may vote on this proposal in the absence of instructions from the beneficial owner.
If there are insufficient votes to approve these proposals, your proxy may be voted by the persons named in the proxy card to adjourn the 2019 Annual Meeting in order to solicit additional proxies in favor of the approval of such proposals.
If the
2019 Annual Meeting is adjourned or postponed for any purpose, at any subsequent reconvening of the
meeting,Annual Meeting, your proxy will be voted in the same manner as it would have been voted at the original convening of the
2019 Annual Meeting unless you withdraw or revoke your proxy.
Could other matters be decided at the Annual Meeting?
Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the Notice of Annual Meeting or brought before such annual meeting by or at the direction of our Board or by a stockholder of record on the Record Date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form of the stockholder’s intention to bring such business before the meeting. As of the date of this Proxy Statement, Replimune does not know of any other mattersbusiness that may be presented for action at the 2019 Annual Meeting. Should any other business properly come before the 2019 Annual Meeting, the persons named on the enclosed proxy will have discretionary authority to vote the shares represented by such proxies in accordance with their best judgment to the same extent as the
person signing the proxy would be entitled to vote. If you hold shares through a broker, bank or other nominee, as described above, they will not be able to vote your shares on any other business that comes before the 2019 Annual Meeting unless they receive instructions from you with respect to such matter.
Why hold a virtual Annual Meeting?
TableAs part of Contentsour effort to maintain a safe and healthy environment for our directors, employees and stockholders who wish to attend the Annual Meeting, in light of COVID-19, we believe that hosting a virtual meeting this year is in our best interest and the best interest of our stockholders. A virtual meeting also enables increased stockholder attendance and participation because stockholders can participate from any location around the world. You will be able to attend the Annual Meeting online and submit your questions by visiting meetings.computershare.com/MACDYTJ. You also will be able to vote your shares electronically at the Annual Meeting by following the instructions above.
What if during the check-in time or during the Annual Meeting I have technical difficulties or trouble accessing the virtual meeting website? We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting website, and the information for assistance will be available during the meeting.
What happens if the meeting is postponed or adjourned?
Your proxy may be voted at the postponed or adjourned meeting. You will still be able to change your proxy until it is voted.
What does it mean if I receive more than one proxy card or voting instruction form?
It means that you have multiple accounts
at the transfer agentwith Computershare or with brokers. Please complete and return all proxy cards or voting instruction forms to ensure that all of your shares are voted.
Where can I find the voting results of the meeting?
Annual Meeting? The preliminary voting results will be announced at the
2019 Annual Meeting. The final results will be disclosed in a Current Report on Form 8-K
filed with the Securities Exchange Commission (the “SEC”) within four business days after the
2019 Annual Meeting date.
What are the implications of being an "emerging“emerging growth company"company” and a “smaller reporting company”?
We are an
"emerging“emerging growth
company"company” as that term is used in the Jumpstart Our Business Startups
(JOBS) Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. These reduced reporting requirements include reduced disclosure about
Replimune'sour executive compensation arrangements and no non-binding advisory votes on executive compensation. We will remain an emerging growth company until the earlier of (1) March 31, 2024, (2) the last day of the fiscal year (a) in which we have total annual gross revenue of at least $1.07 billion, or (b) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior September 30th, and (3) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.
Additionally, we are also a “smaller reporting company” as that term is defined in Regulation S-K. We will remain a smaller reporting company if we have (1) less than $250 million in market value of our shares held by non-affiliates as of the last business day of our second fiscal quarter or (2) less than $100 million of annual revenues in our most recent fiscal year completed before the last business day of our second fiscal quarter and less than $700 million in market value of our shares held by non-affiliates as of the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on
Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Who should I call if I have any additional questions?
If you hold your shares directly, please call Investor Relations at +1 (339) 970-2843. If your shares are held in street name, please contact the telephone number provided on your voting instruction form or contact your broker or nominee holder directly.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALSFOR THE 2021 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON SEPTEMBER 8, 2021 Important Notice Regarding the Availability of Proxy Materials for the
2019 Annual Meeting of Stockholders to be Held on September 4, 2019
The Notice of 2019 Annual Meeting of Stockholders, this Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended March 31, 20192021 are available free of charge at www.envisionreports.com/REPL or at www.replimune.com under "Investors and Media"“Investors & Media” at "Financials“Financials & Filings."
”
PROPOSAL NO. 1—1 — ELECTION OF DIRECTORS
In accordance with Replimune'sReplimune’s certificate of incorporation and bylaws, each as currently amended and in effect, the Board is divided into three classes of directors of approximately equal size. The members of each class of directors are elected to serve a three-year term with the term of office of each class ending in successive years. Philip Astley-Sparke, Kapil Dhingra,Robert Coffin, Hyam Levitsky and Joseph SlatteryDieter Weinand are the Class IIII directors whose terms expire at the 2019 Annual Meeting.
Each of
Philip Astley-Sparke, Kapil Dhingra,Robert Coffin, Hyam Levitsky and
Joseph SlatteryDieter Weinand has been nominated for, and has agreed to stand for, election to the Board to serve as a Class
IIII director of Replimune for three years until the
20222024 Annual Meeting of Stockholders and until
theirhis respective
successors aresuccessor is duly elected and qualified or until his earlier death, resignation or removal.
It is intended that, unless you give contrary instructions, shares represented by proxies will be voted for the election of each of the three nominees listed above as director nominees. Replimune has no reason to believe that any nominee will be unable to serve. In the event that one or more nominees is unexpectedly not available to serve, proxies may be voted for another person nominated as a substitute by the Board, or the Board may reduce the number of directors to be elected at the
2019 Annual Meeting. Information relating to each
nominee for election as director
and for each continuing director,nominee, including his period of service as a director of Replimune, principal occupation and other biographical material, is included below.
A plurality of the votes cast at the meeting will be required for the election of the Class
IIII director nominees. The three nominees for director with the highest number of affirmative votes will be elected as
directors.directors of Replimune. Broker non-votes and
abstentionsvotes withheld will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the election.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR"“FOR”EACH OF THESE NOMINEES FOR CLASS IIII DIRECTOR. (PROPOSAL NO. 1 ON YOUR PROXY CARD)1)
Board Composition and Structure
Our certificate of incorporation and bylaws, each as currently amended and in effect, state that our Board will consist of a number of directors that will be fixed exclusively by the Board from time to time in accordance with the bylaws of the Company. Each director holds office until his successor is duly elected and qualified or until his death, incapacity, resignation or removal. Our certificate of incorporation,
as currently amended and in effect, provides that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the voting power of the outstanding shares of
our capital stock
of Replimune entitled to vote in the election of directors, voting together as a single class, at a meeting of the stockholders called for that purpose. Any vacancy in the Board, including a vacancy that results from an increase in the number of directors, may be filled only by the vote of a majority of the remaining directors then in office, although less than a quorum, or by the sole remaining director.
Our certificate of incorporation, as currently amended and in effect, provides that our Board is divided into three classes of directors, with the classes as nearly equal in number as possible. Each of our directors identified below serves in the class
indicated.indicated opposite such director’s name. Subject to any earlier resignation or removal in accordance with the terms of our certificate of incorporation and bylaws,
each as currently amended and in effect, our current Class III directors, if elected, will serve until the 2024 Annual Meeting of Stockholders; our current Class I directors
if elected, will serve until the 2022 Annual Meeting of Stockholders;
and our current Class II directors will serve until the
2020 Annual Meeting of Stockholders; and our current Class III directors will serve until the 20212023 Annual Meeting of Stockholders. Any additional directorships resulting from an increase in the number of directors will be apportioned by our Board among the three classes as equally as possible.
Our Board is currently
comprisedcomposed of
nineten members. Below is a list of the names, ages as of July
17, 201922, 2021 and classification of the individuals who currently serve as our directors or are nominees to be elected at the
2019 Annual Meeting.
| Name | | | Age | | | Position(s) | | | Class | |
Name
| | Age | | Position(s) | | Class |
|---|
Robert Coffin, Ph.D. Philip Astley-Sparke | | | 5449 | | President, | Chief Executive Officer and Director | | III | I | |
Philip Astley-SparkeRobert Coffin, Ph.D. | | | 4756 | | Executive Chairman, Secretary, Treasurer | President, Chief Research & Development Officer and Director | | I | III | |
| Kapil Dhingra, M.B.B.S.(1)(2)(4) | | | 5961 | | | Director | | | I | |
| Hyam Levitsky, M.D.(3)(4) | | | 6163 | | | Director | | | III | |
Jason Rhodes(2)Paolo Pucci(2)(3)(4) | | | 4960 | | | Director | | | II | |
Joseph Slattery(1)Jason Rhodes(2)(3) | | | 5452 | | | Director | | | II | |
| Joseph Slattery(1)(2) | | | 56 | | | Director | | | I | |
| Sander Slootweg | | | 5052 | | | Director | | | II | |
| Otello Stampacchia, Ph.D.(3) | | | 5052 | | | Director | | | II | |
Dieter Weinand(1)Weinand(1) | | | 5860 | | | Director | | | III | |
Member of the Audit Committee.
(2)
(2)MemberMessrs. Dhingra and Slattery served as members of the Compensation Committee.Committee for all periods during the fiscal year ended March 31, 2021. Mr. Rhodes served as a member of the Compensation Committee until July 28, 2020, on which date Mr. Pucci was appointed to serve in his place.
(3)
(3)MemberDr. Levitsky and Mr. Rhodes served as members of the Nominating and Corporate Governance Committee.Committee for all periods during the fiscal year ended March 31, 2021. Dr. Stampacchia served as a member of the Nominating and Corporate Governance Committee until July 28, 2020, on which date Mr. Pucci was appointed to serve in his place.
(4)
Member of the Research & Development Committee, which was designated as a formal committee of the Board on December 4, 2020.
Recent Board Composition Changes
On April 1, 2020, upon the recommendation of our Nominating and Corporate Governance Committee, our Board increased the size of the Board from nine members to ten, and filled the newly created vacancy on the Board by appointing Paulo Pucci as a director. Mr. Pucci was subsequently elected as a Class II director by our stockholders at our Annual Meeting of Stockholders held on September 9, 2020 and continues to serve as such.
On October 19, 2020, upon the recommendation of our Nominating and Corporate Governance Committee, our Board increased the size of the Board from ten members to eleven, and filled the newly created vacancy on the Board by appointing Tanya Lewis as a director, with such appointment becoming effective as of November 2, 2020. On May 7, 2021, Ms. Lewis tendered her resignation to the Board effective immediately. Subsequently, on May 10, 2021, Ms. Lewis was hired to serve as Replimune’s Chief Development Operations Officer.
On July 15, 2021 the Board decreased the size of the Board from eleven members to ten.
Classified Board
In consultation with our Nominating and Corporate Governance Committee, the Board has determined that the classified board structure remains appropriate
for the Company at this time. A classified board provides for stability, continuity and experience among our Board. Further, the Board believes that building a cohesive board is an important goal. In our industry in particular, long-term focus is critical. The time horizon required for successful development of biologics makes it vital that we have a board that understands the implications of this process and has the ability to develop and implement long-term strategies while benefiting from an in-depth knowledge of
Replimune'sour business and operations. A classified board structure helps to ensure that there will be the continuity and
Table of Contents
stability of leadership required to navigate a challenging development environment while resisting the pressure to focus on short-term results at the expense of theour long-term value and success of the Company. Thesuccess. Our future success of Replimune depends in significant part on the ability to attract and retain capable and experienced directors. In this regard, we believe that longer terms for our directors enhances director independence from both management and stockholder special interest groups.
Information concerning our continuing directors and director nominees is set forth below. The biographical description of each continuing director and director nominee includes the specific experience, qualifications, attributes and skills that led the Board to conclude that such person should serve as a director.
Class IIII Directors (Nominees Standing for Re-Election)Philip Astley-Sparke
Mr. Philip Astley-Sparke is one of our co-founders and has served as our Executive Chairman since our formation in 2015. Since 2016, Mr. Astley-Sparke has served as Chairman of uniQure N.V., a Nasdaq-listed gene therapy company. From 2013 to 2015, Mr. Astley-Sparke served as uniQure N.V.'s President of U.S. operations, where he established its U.S. infrastructure. Mr. Astley-Sparke served as Vice President and General Manager at Amgen, Inc. until December 2011, following Amgen Inc.'s acquisition of BioVex Group, Inc. in March 2011. Mr. Astley-Sparke was previously President and Chief Executive Officer of BioVex Group Inc. Prior to BioVex Group, Inc., Mr. Astley-Sparke was a healthcare investment banker at Chase H&Q and qualified as a Chartered Accountant with Arthur Andersen LLP. Mr. Astley-Sparke has been a Venture Partner at Forbion Capital Partners, a venture capital fund, since May 2012 and serves as Chairman of the board of Oxyrane Limited, a biotechnology company. Mr. Astley-Sparke received a B.Sc. in Cellular and Molecular Pathology from Bristol University. Mr. Astley-Sparke is qualified to serve on our Board because of his extensive knowledge of our Company based on his role as co-founder and Executive Chairman and his extensive financial and leadership experience.
Dr. Kapil Dhingra has been a member of our Board since July 2017. Dr. Dhingra currently serves as the Managing Member of KAPital Consulting, LLC, a healthcare consulting firm that he founded in 2008. Dr. Dhingra also currently serves on the boards of directors of Median Technologies Inc., Five Prime Therapeutics Inc., and Autolus Therapeutics plc, a Nasdaq-listed biopharmaceutical company. Dr. Dhingra previously served as a member of the board of directors of Micromet, Inc., until its acquisition by Amgen, Inc., Advanced Accelerator Applications S.A., until its acquisition by Novartis AG, and YM Biosciences Inc., until its acquisition by Gilead Sciences, Inc., each of which was a public company during Dr. Dhingra's service as a director. From 1999 to 2008, Dr. Dhingra worked at F. Hoffmann-La Roche & Co. where he served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. From 2000 to 2008, he held a Clinical Affiliate appointment at Memorial Sloan Kettering Cancer Center. From 1996 to 1999, Dr. Dhingra worked at Eli Lilly & Co. where he served as Senior Clinical Research Physician. Dr. Dhingra also served as a Clinical Associate Professor of Medicine at the Indiana University School of Medicine from 1997 to 1999. Prior to Eli Lilly & Co., Dr. Dhingra was a member of the faculty of M.D. Anderson Cancer Center from 1989 to 1996. Dr. Dhingra received his M.B.B.S. from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in Internal Medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in Hematology and Oncology at Emory University School of Medicine. Dr. Dhingra is
Table of Contents
qualified to serve on our Board due to his significant experience as a healthcare consultant and as a senior officer of F. Hoffmann-La Roche & Co. and Eli Lilly & Co.
Mr. Joseph Slattery has been a member of our Board since October 2017 and has severed as our lead independent director since March 2019. He has served as Executive Vice President and Chief Financial Officer of TransEnterix, Inc. since 2013. From 2010 to 2013, Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical Inc. Previously, from 1996 to 2007, among other roles, he served as Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp., which was acquired by Qiagen, N.V. Mr. Slattery has served as a member of the board of directors of CVRx Inc. since 2008 and was previously a member of the boards of directors of Exosome Diagnostics Inc. from 2013 to 2018, and Micromet, Inc. from 2007 to 2012, when it was acquired by Amgen, Inc. He earned his Bachelor's Degree in Accounting from Bentley University in 1987 and is a certified public accountant. Mr. Slattery is qualified to serve on our Board based on his experience in public accounting and financial expertise.
Dr. Robert Coffin is one of our co-founders and has served as a member of our Board
since our formation in 2015 and
as our President and Chief Research & Development Officer since January 2020. Previously, Dr. Coffin served as our President and Chief Executive Officer
sincefrom our formation in
2015.2015 to January 2020. From 2013 to 2015, Dr. Coffin served as a consultant for a number of biotechnology companies. From 2011 to 2013, Dr. Coffin served as Vice President of Global Development at Amgen, Inc. In 1999, Dr. Coffin co-founded BioVex Group, Inc., a spin out from his research group at University College London. Dr. Coffin served as the Chief Technology Officer of BioVex Group, Inc. until it was acquired by Amgen, Inc. in 2011. During his time at BioVex
Group, Inc., Dr. Coffin invented all BioVex
Group, Inc. products and oversaw all research and clinical development, including bringing T-Vec into two pivotal Phase 3 clinical trials. Dr. Coffin was awarded a Ph.D. in Virology from Imperial College London prior to his move to University College London in 1991.
We believe Dr. Coffin is qualified to serve on our Board due to his prior experience developing an oncolytic immunotherapy and his extensive knowledge of our Company based on his role as co-founder and President and Chief
ExecutiveResearch & Development Officer.
Dr. Hyam Levitsky has been a member of our Board since May 2018. Since May 2019, Dr. Levitsky has served as President, Research and Development at Century Therapeutics, Inc. and is currently an Adjunct Professor of Oncology, Medicine, and Urology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD where he began as an Assistant Professor of Oncology in 1991, rose to be, a Professor in 2002, and has been an Adjunct Professor since 2011. At Johns Hopkins, Dr. Levitsky served as Scientific Director of the George Santos Bone Marrow Transplant Program from 2005 to 2011. He is a founding member of the Executive Council of the Cancer Immunotherapy Consortium of the Cancer Research Institute where he has served since 2005. Dr. Levitsky is an active member of the American Association of Cancer Research and the American Society of Hematology, and advises the FDA on cancer immunotherapy issues. Previously,Nasdaq-listed
biotechnology company. Dr. Levitsky served as Executive Vice President and Chief Scientific Officer at Juno Therapeutics, Inc. from 2015 to 2018 and was Head of Cancer Immunotherapy Experimental Medicine at F. Hoffmann-La Roche & Co. from 2011 to 2015.
Previously, Dr. Levitsky was Professor of Oncology, Medicine, and Urology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD where he began as an Assistant Professor of Oncology in 1991 and rose to Professor in 2002. At The Johns Hopkins University, Dr. Levitsky served as Scientific Director of the George Santos Bone Marrow Transplant Program from 2005 to 2011. He served on the External Scientific Advisory Board of the Pasteur
Institute'sInstitute’s Center for Human Immunology from 2008 to 2010. Dr. Levitsky holds a number of honors including being named a Stohlman Scholar by the Leukemia and Lymphoma Society in 2002, and was elected as a member of the American Society for Clinical Investigation in 2002.
He was previously an Assistant Chief of Service from 1987 to 1988 and Senior Clinical Fellow
Table of Contents
from 1988 to 1991 at The Johns Hopkins Hospital and The Johns Hopkins Oncology Center, respectively. Dr. Levitsky received a B.S. from the University of Pennsylvania School of Engineering and Applied Science in 1980 and an M.D. from The Johns Hopkins University School of Medicine in 1984. We believe Dr. Levitsky is qualified to serve on our Board because of his experience in management roles at life sciences companies and extensive academic and professional background in the fields of oncology and immunology.
Jason Rhodes Mr. Jason Rhodes has been a member of our Board since September 2015 and a partner at Atlas Ventures since 2014. He has been a Founder and Chairman of Generation Bio, Co. since 2016, a Founder and Chairman of Disarm Therapeutics, Inc. since 2016, and a Founder and the Executive Chairman of Dyne Therapeutics since 2018. He has been a member of the boards of directors of Gemini Therapeutics, Inc. since 2016 and Accent Therapeutics, Inc. since 2017 and was previously a member of the board of directors of Bicycle Therapeutics Limited from 2015 to 2019. From 2010 to 2014, Mr. Rhodes was at Epizyme, Inc., where he most recently served as President and Chief Financial Officer. He led business development at Alnylam Pharmaceuticals, Inc. from 2007 to 2010. Mr. Rhodes obtained a B.A. from Yale University in 1991 and an M.B.A. from the Wharton School of the University of Pennsylvania in 1996. Mr. Rhodes is qualified to serve on our Board based on his extensive leadership experience, his biotechnology company board experience and his experience investing in life science companies.
Mr. Sander Slootweg has been a member of our Board since 2015. Mr. Slootweg co-founded Forbion Capital Partners in 2006 and has served as one of its managing partners since that time. Mr. Slootweg has served on the boards of directors of Forbion Capital Partners' portfolio companies, NorthSea Therapeutics, Inc. since 2017, Oxyrane Limited since 2011, and each of Xention Discovery Ltd. and Ario Pharma Ltd. since 2006. Mr. Slootweg served on the boards of directors of uniQure N.V. from 2012 to 2014, Fovea Pharmaceutics S.A. from 2007 until its sale to Sanofi S.A. in 2009, Argenta Discovery Ltd. from 2001 until its sale to Galapagos N.V. in 2010, BioVex Group, Inc. from 2003 until its sale to Amgen, Inc. in 2011, Alantos Pharmaceuticals, Inc. from 2005 until its sale to Amgen, Inc. in 2007, Impella Cardiosystems AG from 2001 until its sale to Abiomed, Inc. in 2005, and Glycart AG from 2003 until its sale to F. Hoffmann-La Roche & Co. in 2005. Mr. Slootweg has also acted as the chairman of the board of Amsterdam Molecular Therapeutics, the predecessor to uniQure N.V. from 2006 to 2012 and as the chairman of the board of Dezima Pharma B.V. from 2012 until its sale to Amgen, Inc. in 2015. Before co-founding Forbion Capital Partners, he was an investment director at ABN AMRO Capital Life Sciences from 1999 to 2006. Mr. Slootweg holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands. Mr. Slootweg is qualified to serve on our Board because of his extensive leadership experience, his biotechnology company board experience and his experience investing in life science companies.
Otello Stampacchia, Ph.D.
Dr. Otello Stampacchia has been a member of our Board since May 2015. Since 2006, Dr. Stampacchia has been a managing member at Omega Fund Management. Previously, Dr. Stampacchia was in charge of life sciences direct investments at AlpInvest Partners B.V. from 2001 to 2003. Before AlpInvest Partners B.V., from 2000 to 2001, Dr. Stampacchia was the portfolio manager of the Lombard Odier Immunology Fund. Previously, Dr. Stampacchia was a member of the healthcare corporate finance and mergers and acquisitions team at Goldman Sachs Group, Inc. from 1997 to 2000. Before joining Goldman Sachs Group, Inc., Dr. Stampacchia helped co-found the healthcare investment
Table of Contents
activities at Index Securities, now Index Ventures, Inc. Dr. Stampacchia is currently a member of the boards of directors of Kronos Bio, Inc., Gossamer Bio, Inc., Morphic Therapeutic, ESSA Pharma, Inc., and Median Technologies S.A. Dr. Stampacchia received a Ph.D. in Molecular Biology from the University of Geneva, Switzerland in 1997 and a Ph.D. in Biotechnology in 1998. Dr. Stampacchia is qualified to serve on our Board because of his extensive leadership experience, his biotechnology company board experience and his experience investing in life science companies.
Mr. Dieter Weinand has been a member of our Board since June 2018. Since 2018 and Chairperson since April 2020. From November 2018 to March 2020, Mr. Weinand has beenserved as Executive Vice President, Primary Care of Sanofi S.A. He previously served as President, Pharmaceutical Division at Bayer AG from 2014 to 2018. From 2013 to 2014, Mr. Weinand was President, Global Commercialization at Otsuka Pharmaceutical Co., Ltd. and from 2010 to 2013 Mr. Weinand was President, Primary Care and Asia-Pacific Region at Pfizer Inc. From 2001 to 2010, Mr. Weinand served as President, Senior Vice President, and Vice President of Bristol-Myers Squibb Company. Prior to joining Bristol-Myers Squibb Company, Mr. Weinand was Senior Vice President at F.H. Faulding, Inc. from 2000 to 2001, Managing Director, Director, Vice President, and Senior Director at Warner-Lambert Company, which was acquired by Pfizer Inc. in 2000, during the period from 1994 to 2000, Vice President at Pharmos Corporation during 1994, and Director, Area Business Operations Coordinator, and International Product Manager at Lederle International during the period from 1990 to 1994. Mr. Weinand was previously a member the board of directors of Bayer AG, from 2013 to 2014, and HealthPrize Technologies LLC, from 2014 to 2018. Mr. Weinand received a M.S. in Pharmacology and Toxicology from Long Island University in 1987 and a B.A. in Biology from Concordia College in 1982.College. We believe Mr. Weinand is qualified to serve on our Board because of his extensive leadership experience, his experience serving on the boards of biotechnology companies and his experience in management roles at life sciences companies.
Current Directors Not Standing for Re-Election at the Annual Meeting
Philip Astley-Sparke
Mr. Philip Astley-Sparke is one of our co-founders and has served as a member of our Board since our formation in 2015 and as our Chief Executive Officer since January 2020. Previously, Mr. Astley-Sparke served as our Executive Chairman from our formation in 2015 to January 2020. From 2016 until June 2021, Mr. Astley-Sparke served as Chairman of uniQure N.V., a Nasdaq-listed gene therapy company. From 2013 to 2015, Mr. Astley-Sparke served as uniQure N.V.’s President of U.S. operations, where he established its U.S. infrastructure. Mr. Astley-Sparke served as Vice President and General Manager at Amgen, Inc. until December 2011, following Amgen Inc.’s acquisition of BioVex Group, Inc. in March 2011. Mr. Astley-Sparke was previously President and Chief Executive Officer of BioVex Group, Inc. Prior to BioVex Group, Inc., Mr. Astley-Sparke was a healthcare investment banker at Chase H&Q and qualified as a Chartered Accountant with Arthur Andersen LLP. Mr. Astley-Sparke has been a Venture Partner at Forbion Capital Partners, a venture capital fund, since May 2012 and previously served as Chairman of the board of directors of Oxyrane Limited, a biotechnology company, from 2012 to 2020. Mr. Astley-Sparke received a B.Sc. in Cellular and Molecular Pathology from Bristol University. We believe Mr. Astley-Sparke is qualified to serve on our Board because of his extensive knowledge of our Company based on his role as co-founder and Chief Executive Officer and his extensive financial and leadership experience.
Kapil Dhingra, M.B.B.S.
Dr. Kapil Dhingra has been a member of our Board since 2017. Dr. Dhingra currently serves as the Managing Member of KAPital Consulting, LLC, a healthcare consulting firm that he founded in 2008.
Dr. Dhingra also currently serves on the boards of directors of LAVA Therapeutics B.V., where he has served as Chairman since 2021, Black Diamond Therapeutics, Inc., a Nasdaq-listed precision oncology medicine company since January 2021, Median Technologies Inc., since 2017, Five Prime Therapeutics Inc., since 2015, and Autolus Therapeutics plc, a Nasdaq-listed biopharmaceutical company since 2014. Dr. Dhingra previously served as a member of the boards of directors of Micromet, Inc., until its acquisition by Amgen, Inc., Advanced Accelerator Applications S.A., until its acquisition by Novartis AG, and YM Biosciences Inc., until its acquisition by Gilead Sciences, Inc., each of which was a public company during Dr. Dhingra’s service as a director. From 1999 to 2008, Dr. Dhingra worked at F. Hoffmann-La Roche & Co. where he served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. From 2000 to 2008, he held a Clinical Affiliate appointment at Memorial Sloan Kettering Cancer Center. From 1996 to 1999, Dr. Dhingra worked at Eli Lilly & Co. where he served as Senior Clinical Research Physician. Dr. Dhingra also served as a Clinical Associate Professor of Medicine at the Indiana University School of Medicine from 1997 to 1999. Prior to Eli Lilly & Co., Dr. Dhingra was a member of the faculty of M.D. Anderson Cancer Center from 1989 to 1996. Dr. Dhingra received his M.B.B.S. from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in Internal Medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in Hematology and Oncology at Emory University School of Medicine. We believe Dr. Dhingra is qualified to serve on our Board due to his significant experience as a healthcare consultant, his biotechnology company board experience, and his experience as a senior officer of F. Hoffmann-La Roche & Co. and Eli Lilly & Co.
Paolo Pucci
Mr. Paolo Pucci has been a member of our Board since April 2020. From 2008 until its acquisition by Merck & Co. in January 2020, Mr. Pucci served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology and rare diseases company engaged in the research and development of targeted therapeutics. Before joining ArQule, Inc., Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities, including President of the Oncology & Global Specialty Medicines Business Units, and was a member of the Bayer AG Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility with Eli Lilly & Co. from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci currently serves on the boards of directors of West Pharmaceuticals Services, Inc., Merus N.V. and Trillium Therapeutics, Inc., all of which are publicly listed companies, and previously served on the boards of directors of ArQule, Inc., Algeta ASA, until its acquisition by Bayer AG, Dyax Inc., until its acquisition by Shire plc, and NewLink Genetics Inc. Mr. Pucci earned an M.S. in economics and accounting from Università degli Study di Napoli Federico II and an M.B.A. in marketing and finance from the University of Chicago. We believe Mr. Pucci is qualified to serve on our Board because of his extensive leadership experience, his experience serving on the boards of biotechnology companies and his experience in management roles at life sciences companies.
Jason Rhodes
Mr. Jason Rhodes has been a member of our Board since 2015. Since 2014, Mr. Rhodes has been a partner at Atlas Ventures, a venture capital firm. From 2010 to 2014, Mr. Rhodes was at Epizyme, Inc., where he most recently served as President and Chief Financial Officer. Prior to that, he led business development at Alnylam Pharmaceuticals, Inc. from 2007 to 2010. Mr. Rhodes currently serves as the chairman of the board of directors of Generation Bio Co, as the chairman of the board of directors of Dyne Therapeutics, Inc., and a member of the board of directors of Gemini Therapeutics, Inc. Mr. Rhodes obtained a B.A. from Yale University in 1991 and an M.B.A. from the Wharton School of the University of Pennsylvania in 1996. We believe Mr. Rhodes is qualified to serve on our Board based on his extensive leadership experience, his biotechnology company board experience, and his experience investing in life science companies.
Sander Slootweg
Mr. Sander Slootweg has been a member of our Board since 2015. Mr. Slootweg co-founded Forbion Capital Partners in 2006 and has served as one of its managing partners since that time. Mr. Slootweg has served on the boards of directors of Forbion Capital Partners’ portfolio companies, NorthSea Therapeutics,
Inc. since 2017, Oxyrane Limited since 2011, and each of Xention Discovery Ltd. and Ario Pharma Ltd. since 2006. Mr. Slootweg served on the boards of directors of uniQure N.V. from 2012 to 2014, Fovea Pharmaceutics S.A. from 2007 until its sale to Sanofi S.A. in 2009, Argenta Discovery Ltd. from 2001 until its sale to Galapagos N.V. in 2010, BioVex Group, Inc. from 2003 until its sale to Amgen, Inc. in 2011, Alantos Pharmaceuticals, Inc. from 2005 until its sale to Amgen, Inc. in 2007, Impella Cardiosystems AG from 2001 until its sale to Abiomed, Inc. in 2005, and Glycart AG from 2003 until its sale to F. Hoffmann-La Roche & Co. in 2005. Mr. Slootweg has also acted as the Chairman of the board of Amsterdam Molecular Therapeutics, the predecessor to uniQure N.V., from 2006 to 2012 and as the Chairman of the board of Dezima Pharma B.V. from 2012 until its sale to Amgen, Inc. in 2015. Before co-founding Forbion Capital Partners, he was an investment director at ABN AMRO Capital Life Sciences from 1999 to 2006. Mr. Slootweg holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands. We believe Mr. Slootweg is qualified to serve on our Board because of his extensive leadership experience, his biotechnology company board experience and his experience investing in managementlife science companies.
Joseph Slattery
Mr. Joseph Slattery has been a member of our Board since 2017. He previously served as our lead independent director from March 2019 until March 31, 2020. He served as Executive Vice President and Chief Financial Officer of Asensus Surgical, Inc. from October 2013 through December 2019. From 2010 to 2013, Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc. Previously, from 1996 to 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, including as Chief Financial Officer and Senior Vice President of Finance and Information Systems from 2006 to 2007. Mr. Slattery serves on the boards of directors of Omega Alpha SPAC, Morphic Therapeutic, Inc. and CVRx Inc., and he previously served as a director of Baxano Surgical, Inc., Exosome Diagnostics, Inc. and Micromet, Inc. Mr. Slattery received a B.S. in Accounting from Bentley University and is a certified public accountant. We believe Mr. Slattery is qualified to serve on our Board based on his experience in public accounting and financial expertise.
Otello Stampacchia, Ph.D.
Dr. Otello Stampacchia has been a member of our Board since 2015. Dr. Stampacchia has served as founder and Managing Director of Omega Funds since November 2004. Previously, Dr. Stampacchia was in charge of life sciences direct investments at AlpInvest Partners B.V. from 2001 to 2003. Before AlpInvest Partners B.V., from 2000 to 2001, Dr. Stampacchia was the portfolio manager of the Lombard Odier Immunology Fund. Previously, Dr. Stampacchia was a member of the healthcare corporate finance and mergers and acquisitions team at Goldman Sachs Group, Inc. from 1997 to 2000. Before joining Goldman Sachs Group, Inc., Dr. Stampacchia helped co-found the healthcare investment activities at Index Securities, now Index Ventures, Inc. Dr. Stampacchia is currently a member of the boards of directors of Kronos Bio, Inc. Ikena Oncology, Inc. and Omega Alpha SPAC. Dr. Stampacchia also serves on the boards of directors of a number of private companies and previously served on the boards of directors of Gossamer Bio, Inc., Morphic Therapeutics, Inc. and ESSA Pharma, Inc. Dr. Stampacchia received a Ph.D. in Molecular Biology from the University of Geneva, Switzerland in 1997 and a Ph.D. in Biotechnology in 1998. We believe Dr. Stampacchia is qualified to serve on our Board because of his extensive leadership experience, his biotechnology company board experience and his experience investing in life science companies.
Under the rules and regulations of
theThe Nasdaq Stock Market
LLC, or Nasdaq, a majority of a listed
company'scompany’s board of directors must be
comprisedcomposed of independent directors. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed
company'scompany’s audit committee and compensation committee be independent and satisfy additional independence criteria set forth in Rules 10A-3 and 10C-1, respectively, under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under Nasdaq rules, a director will only qualify as an
"independent director"“independent director” if, in the opinion of that
company'scompany’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.
Based upon information requested from and provided by our directors and nominees concerning their background, employment and affiliations, including family relationships, our Board has determined, upon the recommendation of our Nominating and Corporate Governance Committee, that each of our directors and nominees other than
Philip Astley-Sparke, our Chief Executive Officer, and Robert Coffin, Ph.D., our President and Chief
ExecutiveResearch & Development Officer,
and Philip Astley-Sparke, our Executive Chairman, Secretary, and Treasurer, has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent within the meaning of the director independence standards of Nasdaq and
the Securities Exchange Commission, or SEC rules and regulations. Our Board has also determined that each of the current members of our Audit Committee and our Compensation Committee as set forth in the
"Board Committees"“Board Committees” section below satisfies the independence standards for such committee. In making such determination, our Board considered the relationships that each non-employee director has with Replimune and all other facts and circumstances deemed relevant in determining their independence.
There are no family relationships among any of our directors, nominees or executive officers.
Board Meetings, Attendance and Executive Sessions
The Board held
four (4)seven (7) meetings and took action by written consent two (2) times during the fiscal year ended March 31,
2019.2021. All board members attended at least 75% of the meetings of the Board and the committees of the Board on which they served.
Executive sessions, or meetings of the outside (non-management) directors without management present, are held regularly. The non-management directors met in executive session during eachfour (4) of the regularly scheduledseven (7) Board meetings during the fiscal year ended March 31, 2019.
Replimune encourages its2021. We encourage our directors to attend theour Annual Meeting of Stockholders.
Stockholders, which we have historically held immediately after a meeting of the Board. As no stockholders attended in person our 2020 Annual Meeting of Stockholders, which was held virtually, Dieter Weinand, Philip Astley-Sparke, Robert Coffin, Kapil Dhingra, Paolo Pucci, Jason Rhodes, and Joseph Slattery attended the 2020 Annual Meeting of Stockholders via teleconference.
Board of Directors Leadership Structure
The positions of
chairmanchairperson of the Board and chief executive officer are presently separated. Our Board recognizes the time, effort and energy that the chief executive officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our
chairman,chairperson, particularly as the
Board'sBoard’s oversight responsibilities continue to grow. Our Board believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
Effective as of April 1, 2020, Dieter Weinand was appointed as the Chairperson of the Board. Prior to Mr. Weinand’s appointment as the Chairperson of the Board, Philip Astley-Sparke served as the Executive Chairman of the Board and Joseph Slattery served as the lead independent director of the Board. The Board established the position of lead independent director of the Board while Mr. Astley-Sparke
servesserved as Executive Chairman
of our Board. Given Mr. Astley-Sparke's executive role, the Board has appointed a lead independent directorin order to provide an additional measure of balance, to ensure the
Board'sBoard’s independence, and to enhance the
Board'sBoard’s ability to fulfill its management oversight responsibilities.
JosephConcurrently with Mr. Weinand’s appointment as the Chairperson of the Board, Mr. Slattery
currently servesstepped down as the lead independent
director. The lead independent director
is responsible for (i) calling and presiding over meetings of the
Table of Contents
independent members of the Board; (ii) calling meetings of the Board; (iii) acting as the principal liaison between the independent members of the Board and the executive chairman and/or chief executive officer; (iv) advising the executive chairman and/or chief executive officer as to the quality, quantity, and timeliness of the flow of information from management to the Board that is necessary for the independent directors to perform their duties effectively and responsibly; (v) advising the executive chairman and/or chief executive officer on such other matters deemed appropriateposition will remain vacant until otherwise determined by the lead independent director; and (vi) assuming such other duties as theBoard.
The Board may designate from time to time.of Directors’ Role of the Board in Risk Oversight
The Company's
Our management
team is responsible for the day-to-day management of the risks we face, while our Board, as a whole and through committees, has responsibility for the oversight of risk management. Our Board performs this oversight role by using several different levels of review. In connection with its reviews of the operations and corporate functions of our company, our Board addresses the primary risks associated with those operations and corporate functions. In addition, our Board reviews the risks associated with our
company'scompany’s business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies.
The role of the Board in overseeing the management of our risks is conducted primarily through committees of the Board, as described in the descriptions of each of the committees below and in the charters of each such committee. The full Board (or the appropriate Board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures,
thetheir potential impact on us, and the steps we take to manage them. When a Board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairperson of the relevant committee reports on the discussion to the full Board during the committee reports portion of the next Board meeting. This enables the Board and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.
Our Board has established an Audit Committee, a Compensation Committee,
and a Nominating and Corporate Governance
Committee, and a Research & Development Committee, each of which operates pursuant to a charter adopted by our Board. Each committee
other than the Research & Development Committee reviews and assesses the adequacy of its charter annually and recommends any proposed changes to the Board for approval. The
Research & Development Committee will review its charter from time to time as deemed necessary by the members thereof. The charters for
the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committeeeach of our Board committees are all available on our website at www.replimune.com under
"Investors and Media"“Investors & Media” at
"Corporate“Corporate Governance.
"”
The composition and responsibilities of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our Board. The following table describes which directors serve on each of the Board committees.
| Name: | | | | | | | | | | |
Name:
| | Nominating and Corporate
Governance Committee | | (1) | | | Compensation
Committee | | (2) | | | Audit
Committee | | | | R&D
Committee(3) | |
|---|
| Kapil Dhingra, M.B.B.S. | | | | | | | | | | | X | | | | | | X | | | | | | X | | |
| Hyam Levitsky, M.D. | | | | | X | | | | | | | | | | | | | | | | | | X | | |
| Paolo Pucci | | | | | X | | | | | | X | | | | | | | | | | | | X | | |
| Jason Rhodes | | | | | X | | | X | | | | | | | | | | | | | | | | | |
| Joseph Slattery | | | | | | | | | | | X | | | | | | X | | | | | | | | |
| Otello Stampacchia, Ph.D. | | | X | | | | | | | | | | | | | | | | | | | | | | |
| Dieter Weinand | | | | | | | | | | | | | | | | | X | | | | | | | | |
(1)
TableDr. Levitsky and Mr. Rhodes served as members of Contentsthe Nominating and Corporate Governance Committee for all periods during the fiscal year ended March 31, 2021. Dr. Stampacchia served as a member of the Nominating and Corporate Governance Committee until July 28, 2020, on which date Mr. Pucci was appointed to serve in his place.
(2)
Messrs. Dhingra and Slattery served as members of the Compensation Committee for all periods during the fiscal year ended March 31, 2021. Mr. Rhodes served as a member of the Compensation Committee until July 28, 2020, on which date Mr. Pucci was appointed to serve in his place.
(3)
Each member of the Research & Development Committee began serving in such role on December 2, 2020, the date on which the Research & Development Committee was designated by the Board as a formal committee of the Board. Ms. Lewis served as a member of the Research &
Development Committee until her resignation from the Board on May 7, 2021. No director was appointed to serve in her place.
The Audit Committee provides oversight of our accounting and financial reporting process, the audit of our financial statements and our internal control function. Among other matters, the Audit Committee is responsible for the following:
•
assisting the Board in oversight of the independent auditors'auditors’ qualifications, independence and performance;
•
•the engagement, retention and compensation of the independent auditors;
•
•reviewing the scope of the annual audit and reviewing and discussing with management and the independent auditors the results of the annual audit and the review of our quarterly financial statements, including the disclosures in our annual and quarterly reports filed with the SEC;
•
•reviewing our risk assessment and risk management processes;
•
•reviewing policies and procedures with respect to our related party transactions policy;
•
•establishing procedures for receiving, retaining and investigating complaints received by us regarding accounting, internal accounting controls or audit matters; and
•
•approving audit and permissible non-audit services provided by our independent auditor.
The
current members of our Audit Committee
areis comprised of Kapil Dhingra, Dieter Weinand, and Joseph Slattery, who is the
chairchairperson of the Audit Committee. All members of
ourthe Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our Board has determined that Mr. Slattery is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication under the applicable rules and regulations of Nasdaq as a result of, among other things, his senior-level executive experience, including his service as Chief Financial Officer of
TransEnterix,Asensus Surgical, Inc.
sincefrom 2013
to 2019 and Baxano Surgical Inc. from 2010 to 2013, and Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp until 2007. All of the members of
ourthe Audit Committee are independent directors as defined under the applicable rules and regulations of the SEC and Nasdaq.
During the fiscal year ended March 31,
2019,2021, the Audit Committee met
five (5)four (4) times and
did not taketook action by written
consent.consent two (2) times. The report of the Audit Committee is included in this Proxy Statement under
"Audit“Audit Committee Report.
"”
Compensation Committee Our
The Compensation Committee adopts and administers the compensation policies, plans and benefit programs for our executive officers and all other members of our executive team.
OurThe Compensation Committee is also responsible for making recommendations regarding non-employee director compensation to the full Board. In addition, among other things,
ourthe Compensation Committee evaluates annually, in consultation with the Board, the performance of our Chief Executive Officer, reviews and approves corporate goals and objectives relevant to compensation of our Chief Executive Officer and other executives and evaluates the performance of these executives in light of those goals and objectives.
OurThe Compensation Committee also administers our equity compensation plans. The current members of
ourthe Compensation Committee are Joseph Slattery,
Jason Rhodes,Paolo Pucci, and Kapil Dhingra, who is the
chairchairperson of the Compensation Committee. All members of our Compensation Committee are independent under the applicable rules and regulations of the SEC and Nasdaq.
During the fiscal year ended March 31, 2019,2021, the Compensation Committee met three (3) times and took action by written consent two (2)three (3) times.
Table of Contents
Nominating and Corporate Governance Committee
Our
The Nominating and Corporate Governance Committee is responsible for, among other things, making recommendations regarding corporate governance, the composition of our Board, the identification,
evaluation and nomination of director candidates and the structure and composition of committees of our Board. In addition,
ourthe Nominating and Corporate Governance Committee oversees our corporate governance guidelines, reviews and assesses the adequacy of our committee charters, oversees compliance with our code of business conduct and ethics, and contributes to succession planning. The current members of
ourthe Nominating and Corporate Governance Committee are
Otello Stampacchia,Paolo Pucci, Hyam Levitsky, and Jason Rhodes, who is the
chairchairperson of the Nominating and Corporate Governance Committee. All of the members of
ourthe Nominating and Corporate Governance Committee are independent under the applicable rules and regulations of Nasdaq.
During the fiscal year ended March 31, 2019,2021, the Nominating and Corporate Governance Committee met three (3) times and took action by written consent two (2) times.
Research & Development Committee
The Research & Development Committee was designated as a formal committee of the Board in December 2020 and met one (1) time, and did not take any action by written
consent.consent, during the fiscal year ended March 31, 2021. The primary purpose of the Research & Development Committee is to provide guidance to management and the Board on matters related our research and development efforts and product pipeline. Specifically, the Research and Development Committee is responsible for, among other things, providing input on our preclinical studies, clinical trials and clinical development risks, assessing of our program’s and product candidate’s progress against their respective targets, and summarizing significant findings of our research and development efforts and product pipeline to the full Board.
The Research & Development Committee is currently comprised of and Kapil Dhingra, Paolo Pucci and Hyam Levitsky, who is the chairperson of the Research & Development Committee. Although neither the SEC nor Nasdaq require that the members of the Research & Development Committee be independent, each member of the Research & Development Committee satisfies the independence standards established by SEC and Nasdaq.
Policies Governing Director Nominations
Director Nomination Process Our Board is responsible for selecting its own members. The Board delegates the selection and nomination process to the Nominating and Corporate Governance Committee, with the expectation that other members of the Board and of management will be requested to take part in the process as appropriate. The Nominating and Corporate Governance Committee makes recommendations to the Board regarding the size and composition of the Board. The Nominating and Corporate Governance Committee reviews annually with the Board the composition of the Board as a whole and recommends, if necessary, measures to be taken so that the Board reflects the appropriate balance of expertise, experience, qualifications, diversity and skills required for the Board as a whole and contains at least the minimum number of independent directors required by applicable laws, rules and regulations.
TheUnless determined otherwise by the Board, the Nominating and Corporate Governance Committee recommends, and the Board nominates, candidates to stand for election as directors.
The Nominating and Corporate Governance Committee, recommended to the Board that the three nominees listed above be nominated for election as Class III directors at the Annual Meeting.
Generally, our Nominating and Corporate Governance Committee identifies candidates for director nominees in consultation with management, through the use of search firms or other advisors, through recommendations submitted by stockholders or through such other methods as the Nominating and Corporate Governance Committee deems to be helpful to identify candidates. Once candidates have been identified, our Nominating and Corporate Governance Committee confirms that the candidates meet all of the minimum qualifications for director nominees established by the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee may gather information about the candidates through interviews, detailed questionnaires, background checks or any other means that the Nominating and Corporate Governance Committee deems to be appropriate in the evaluation process. The Nominating and Corporate Governance Committee then meets as a group to discuss and evaluate the qualifications and skills of each candidate, both on an individual basis and taking into account the overall
composition and needs of the Board. Based on the results of the evaluation process, the Nominating and Corporate Governance Committee recommends to the Board for approval candidates as director nominees for election to the Board.
Stockholders may also nominate persons to be elected as directors. The Nominating and Corporate Governance Committee will consider director candidates recommended by our stockholders in accordance with our bylaws. If a stockholder wishes to nominate a person for election as director, such stockholder must follow the procedures contained in our bylaws. In evaluating candidates recommended by our stockholders, the Nominating and Corporate Governance Committee applies the same criteria set forth below under
"Minimum“Minimum Qualifications.
"” To nominate a person to stand for
Table of Contents
election as a director, a stockholder must provide our Secretary with timely notice of the nomination and the notice must include the information required by Section 2.12(b) of our bylaws.
Additional information regarding requirements for stockholder nominations for next
year'syear’s annual meeting is described in this Proxy Statement under
"General Matters—“General Matters — Stockholder Proposals and Nominations.
"”
In considering whether to recommend any particular candidate for inclusion in the slate of recommended director nominees for the Board, our Nominating and Corporate Governance Committee may consider certain criteria set forth in the Nominating and Corporate Governance Committee Charter. These criteria include the
Board'sBoard’s size and current composition; corporate governance policies; applicable Nasdaq listing standards and SEC rules and regulations; a
candidate'scandidate’s individual director performance, expertise, experience, qualifications, attributes, diversity, skills and willingness to serve actively; the number of other public and private boards on which a candidate sits; and the absence of potential conflicts with our interests. The Board does not assign specific weights to particular criteria and no particular criterion is a prerequisite for any prospective nominee.
In evaluating proposed director candidates
our(both proposed director candidates and current Board members), the Nominating and Corporate Governance Committee may consider, in addition to the minimum qualifications and other criteria for board membership approved by the Board from time to time, all facts and circumstances that it deems appropriate or advisable, including, among other things, diversity, not limited to race, gender or national
origin. Weorigin, the skills of the proposed director candidate, his or her depth and breadth of professional experience or other background characteristics, his or her independence and the needs of the Board. Although we have no formal policy regarding board
diversity. Ourdiversity, we consider diversity in our Board’s makeup, and our Nominating and Corporate Governance
Committee's and our Board'sCommittee’s priority in selecting Board members is the identification of persons who will further the interests of
our stockholdersthe Company through
theiran established record of professional accomplishment, the ability to contribute positively to the collaborative culture among
our Board members, knowledge of our business, understanding
of the competitive landscape, and professional and personal experiences and expertise relevant to our growth strategy.
The Nominating and Corporation Governance Committee will consider candidates recommended by stockholders.Communication with the Board of Directors
and Stockholder Engagement We welcome feedback and value regular dialogue with our stockholders. We expect to continue to engage with our stockholders prior to the Annual Meeting and, as a matter of policy and practice, foster and encourage engagement with our stockholders on an ongoing basis. Stockholders wishing to communicate with our Board may do so by writing to the Board or to the non-employee members of the Board as a group, at:
Replimune Group, Inc.18 Commerce Way500 Unicorn ParkWoburn, MA 01801Attention: Investor Relations The communication must prominently display the legend "BOARD COMMUNICATION"“BOARD COMMUNICATION” in order to indicate to Investor Relations that it is a communication for the Board. Upon receiving such a communication, Investor Relations will promptly forward the communication to the relevant individual or group to which
it is addressed. Certain items that are unrelated to the
Board'sBoard’s duties and responsibilities may be excluded, such as spam, junk mail and mass mailings, resumes and other forms of job inquiries, surveys and business solicitations or advertisements. Investor Relations will not forward any communication determined in good faith belief to be frivolous, unduly hostile, threatening, illegal or similarly unsuitable.
Compensation Committee Interlocks and Insider Participation
During the last completed fiscal year Kapil Dhingra, Joseph Slattery, and Jason Rhodes served on the Compensation Committee. None of the members of our Compensation Committee has at any time
Table of Contents
during the prior fiscal year been one of our officers or employees. None of the members of the Compensation Committee during the prior fiscal year were formerly one of our officers. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board or compensation committee of any entity that has one or more executive officers serving on our Board or Compensation Committee.
Code of Business Conduct and Ethics and Corporate Governance Guidelines
We have adopted a code of business conduct and ethics that applies to all of our employees, including our executive officers and
directors, and those employees responsible for financial
reporting.reporting, and directors. The code of business conduct and ethics is available on our website at www.replimune.com under
"Investors“Investors and
Media"Media” at
"Corporate Governance"“Corporate Governance”; or by requesting a copy, free of charge, in writing from Investor Relations at Replimune Group, Inc.,
18 Commerce Way,500 Unicorn Park, Woburn, MA 01801. We intend to post on our website any amendment to, or waiver under, a provision of the code of business conduct and ethics that applies to certain of our executive officers within four business days following the date of such amendment or waiver.
A copy of our corporate governance guidelines may also be accessed free of charge by visiting our website at www.replimune.com under "Investors and Media"“Investors & Media” at "Corporate Governance"“Corporate Governance” or by requesting a copy from Investor Relations at our principal executive offices above.
Anti-Hedging and Pledging Policy
Pursuant to our Insider Trading Policy, we prohibit our employees, our executive officers, members of the Board, and certain consultants and contractors from engaging in any hedging or monetization transactions relating to our securities, including through the use of financial instruments such as prepaid variable forwards contracts, equity swaps, collars and exchange funds. We also prohibit our employees, our executive officers, members of the Board, and certain consultants and contractors from holding our securities in a margin account or otherwise pledging our securities as collateral for a loan.
We pay our non-employee directors retainers in cash. We do not pay any compensation to our President and Chief Executive Officeremployee directors in connection with histheir service on our Board. The compensation that we pay to our President and Chief Executive Officeremployee directors is discussed in the "Executive Compensation"“Executive Compensation” section of this Proxy Statement. For the fiscal year ended March 31, 2019,2021, each non-employee director other than the Chairman of the Board (the “Chair”) received an annual retainer fee of $35,000 paid in quarterly installments. The Chair received an annual retainer fee of $66,500 paid in quarterly installments. In addition, non-employee directors received the following, as applicable:
| Non-Employee Director | | | Annual Fee | |
| Chairperson of the Audit Committee | | | | $ | 15,000 | | |
| Member of the Audit Committee (other than chairperson) | | | | $ | 7,500 | | |
| Chairperson of the Compensation Committee | | | | $ | 10,000 | | |
| Member of the Compensation Committee (other than chairperson) | | | | $ | 5,000 | | |
| Chairperson of the Nominating and Corporate Governance Committee | | | | $ | 8,000 | | |
| Member of the Nominating and Corporate Governance Committee (other than chairperson) | | | | $ | 4,000 | | |
| Chairperson of the Research & Development Committee | | | | $ | 10,000 | | |
| Member of the Research & Development Committee (other than chairperson) | | | | $ | 5,000 | | |
Upon the recommendation of the Compensation Committee and following a competitive market review prepared by the Compensation Committee’s independent compensation consultant, the Board approved a $5,000 increase to the annual retainer fee payable to the non-employee members of our Board from $35,000 to $40,000, effective as of April 1, 2021. The Board also approved increasing the annual cash fees payable to (i) the chairperson of each of the Compensation Committee, Nominating and Corporate Governance Committee and Research & Development Committee by $2,000 and (ii) the members of the Compensation Committee, Nominating and Corporate Governance Committee and Research & Development Committee (other than the chairperson of each such committee) by $1,000, in each case, effective as of April 1, 2021.
| | | | |
Non-Employee Director | | Annual Fee | |
|---|
Lead Independent Director | | $ | 17,500 | |
Chairman of the Audit Committee | | $ | 15,000 | |
Member of the Audit Committee (other than chairman) | | $ | 7,500 | |
Chairman of the Compensation Committee | | $ | 10,000 | |
Member of the Compensation Committee (other than chairman) | | $ | 5,000 | |
Chairman of the Nominating and Corporate Governance Committee | | $ | 8,000 | |
Member of the Nominating and Corporate Governance Committee (other than chairman) | | $ | 4,000 | |
We also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings.
In connection with our initial public offering, each member of our Board received an option to purchase up to 13,500 shares of our common stock, other than Dr. Levitsky and Mr. Weinand, who each received an option to purchase up to 27,000 shares of our common stock, in each case under our 2018 Omnibus Incentive Compensation Plan. Twenty-five percent (25%) However, as a result of the shares underlying these options vested on July 19, 2019 andCOVID-19 pandemic, we did not organize any in-person Board or committee meetings during the remainder of the shares underlying these option vest in twenty-four (24) equal monthly installments thereafter. In addition, onfiscal year ended March 31, 2021.
On April 1 of each year, each continuing non-employee director who has served on the Board is eligible to receive an option grant to purchase shares of our common stock.stock under our 2018 Omnibus Incentive Compensation Plan. On each of April 1, 2019,2020 and 2021, we awarded each continuing non-employee director, other than Joseph Slattery and Dieter Weinand, an option to purchase up to 16,500 shares of our common stock. Joseph Slattery was awarded an option to purchase up to 24,249 and 16,500 shares of our common stock on April 1, 2020 and 2021, respectively. Dieter Weinand was awarded an option to purchase up to 24,750 shares of our common stock on April 1, 2020 and 2021. All such director wasoptions have vested or will vest in full upon the one-year anniversary of the date of grant.
In addition, in connection with their respective appointments as a member of our Board during the fiscal year ended March 31, 2021, Paolo Pucci and Tanya Lewis were each granted an option to purchase up to 13,50033,000 shares of our common stock which willon April 1, 2020 and November 2, 2020, respectively. Twenty-five percent (25%) of the shares underlying such options vest in full uponon the firstone-year anniversary of the date of grant.grant and the remainder of the shares underlying such options vest in twenty-four (24) equal monthly installments thereafter. The exercise price for each of these option grants wasis equal to the fair market valueclosing price of our common stock on the date of grant. Pursuant to our 2018 Omnibus Incentive Compensation Plan, the option granted to Ms. Lewis was terminated and cancelled on May 7, 2021 upon her resignation from the Board.
Each
such grantof the above grants was, and each annual grant going forward will be, subject to approval by our Board at the time of grant.
The following table sets forth information regarding compensation earned by our non-employee directors during the fiscal year ended March 31, 2019:2021:
| Name | | | Fees earned in
cash ($)(1) | | | Option
Awards ($)(2) | | | Total ($) | |
| Kapil Dhingra, M.B.B.S. | | | | | 54,153 | | | | | | 103,841 | | | | | | 157,994 | | |
| Hyam Levitsky, M.D. | | | | | 42,306 | | | | | | 103,841 | | | | | | 146,148 | | |
Tanya Lewis(3) | | | | | 16,235 | | | | | | 916,912 | | | | | | 933,146 | | |
| Paolo Pucci | | | | | 42,653 | | | | | | 211,025 | | | | | | 253,678 | | |
| Jason Rhodes | | | | | 44,667 | | | | | | 103,841 | | | | | | 148,508 | | |
| Joseph Slattery | | | | | 55,000 | | | | | | 152,609 | | | | | | 207,609 | | |
| Sander Slootweg | | | | | 35,000 | | | | | | 103,841 | | | | | | 138,841 | | |
Otello Stampacchia, Ph.D.(4) | | | | | — | | | | | | 103,841 | | | | | | 103,841 | | |
| Dieter Weinand | | | | | 74,000 | | | | | | 155,762 | | | | | | 229,762 | | |
| | | | | | | | | | |
Name | | Fees earned in
cash ($)(1) | | Option
Awards ($)(2)(3) | | Total ($) | |
|---|
Kapil Dhingra, M.B.B.S. | | | 38,574 | | | 117,585 | | | 156,159 | |
Hyam Levitsky, M.D. | | | 27,360 | | | 235,170 | | | 262,530 | |
Jason Rhodes | | | 33,678 | | | 117,585 | | | 151,263 | |
Joseph Slattery(4) | | | 41,240 | | | 117,585 | | | 158,825 | |
Sander Slootweg(5) | | | 26,892 | | | 117,585 | | | 144,477 | |
Otello Stampacchia, Ph.D.(6) | | | — | | | 117,585 | | | 117,585 | |
Dieter Weinand(5) | | | 27,477 | | | 235,170 | | | 262,647 | |
(1)(1)- Amounts represent cash compensation earned for services rendered by each non-employee member of the Board for the fiscal year ended March 31,
2019.
2021.
(2)
Table of Contents
(2)Twenty-five percent (25%) of the shares underlying these options vested on July 19, 2019 and the remainder of the shares underlying these options vest in twenty-four (24) equal monthly installments thereafter. These options have a weighted average exercise price of $8.71 per share.
(3)- Amounts shown reflect the grant date fair value of options awarded during the fiscal year ended March 31,
20192021 determined in accordance with the Financial Accounting Standards Board, Accounting Standards Codification Topic 718,Compensation—Compensation — Stock Compensation.
(4)Mr. Slattery was appointed by Assumptions used in the Board as the Company's lead independent directorcalculation of these amounts are included in Note 9 to our financial statements in our Annual Report on March 13, 2019. The amount shown includes the cash retainer earned by Mr. Slattery for service as the Company's lead independent director from such date through March 31, 2019.
(5)On November 15, 2018, Mr. Weinand replaced Mr. Slootweg as a member of our audit committee. The amount shown includes the cash retainer earned by each such director for their service as a member of our audit committeeForm 10-K for the fiscal year ended March 31, 2019.2021. These amounts do not reflect the actual economic value that will be realized by the director upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.
(3)
Tanya Lewis was granted an option to purchase up to 33,000 shares of our common stock on November 2, 2020. Pursuant to our 2018 Omnibus Incentive Compensation Plan, the option granted to Ms. Lewis was terminated and cancelled on May 7, 2021 upon her resignation from the Board. The incentive awards granted to Ms. Lewis on May 10, 2021 in her capacity as our Chief Development Operations Officer are not included herein.
(4)
(6)Dr. Stampacchia forfeiteddeclined the $27,360$39,000 cash retainer that he earnedwas otherwise payable to him during the fiscal year ended March 31, 20192021 for his service as a member of our Board and our Nominating and Corporate Governance Committee.
The following table sets forth, as of March 31, 2019,2021, the aggregate number of exercisable and unexercisable option awards outstanding held by our non-employee directors at that time.time:
| | | | Option Awards | |
Name(1) | | | Exercisable | | | Unexercisable | |
| Kapil Dhingra, M.B.B.S. | | | 140,505 | | | 18,205 | |
| Hyam Levitsky, M.D. | | | 37,110 | | | 19,890 | |
Tanya Lewis(1) | | | 0 | | | 33,000 | |
| Paolo Pucci | | | 0 | | | 33,000 | |
| Jason Rhodes | | | 25,295 | | | 18,205 | |
| Joseph Slattery | | | 45,564 | | | 30,325 | |
| Sander Slootweg | �� | | 25,295 | | | 18,205 | |
| Otello Stampacchia, Ph.D. | | | 25,295 | | | 18,205 | |
| Dieter Weinand | | | 37,110 | | | 28,140 | |
(1)
Tanya Lewis was granted an option to purchase up to 33,000 shares of our common stock on November 2, 2020. Pursuant to our 2018 Omnibus Incentive Compensation Plan, the option granted to Ms. Lewis was terminated and cancelled on May 7, 2021 upon her resignation from the Board.
| | | | | | | |
| | Option Awards | |
|---|
Name | | Exercisable | | Unexercisable | |
|---|
Kapil Dhingra, M.B.B.S. | | | 155,210 | | | 13,500 | |
Hyam Levitsky, M.D. | | | — | | | 27,000 | |
Jason Rhodes | | | — | | | 13,500 | |
Joseph Slattery | | | 10,565 | | | 32,775 | |
Sander Slootweg | | | — | | | 13,500 | |
Otello Stampacchia, Ph.D. | | | — | | | 13,500 | |
Dieter Weinand | | | — | | | 27,000 | |
20
Below is a list of the names, ages as of July
17, 2019,22, 2021, positions, and a brief account of the business experience of the individuals who serve,
or have been chosen to serve, as our executive officers.
| Name | | | Age | |
Name
| | Age | | Position(s) |
|---|
Robert Coffin, Ph.D. | | 54Position(s) | | President and Chief Executive Officer |
| Philip Astley-Sparke | | 47 | 49 | | | Chief Executive Chairman, Secretary,Officer | |
| Robert Coffin, Ph.D. | | | 56 | | | President and Chief Research & Development Officer | |
| Andrea Pirzkall, M.D. | | | 51 | | | Chief Medical Officer | |
| Jean Franchi | | | 54 | | | Chief Financial Officer and Treasurer | |
| Colin Love, Ph.D. | | 61 | 63 | | | Chief Operating Officer | |
| Pamela Esposito, Ph.D. | | 45 | 47 | | | Chief Business Officer | |
Howard Kaufman, M.D. Sushil Patel, Ph.D. | | 58 | 50 | | | Chief MedicalCommercial Officer | |
Stephen GorgolTanya Lewis | | 60 | 50 | | | Chief AccountingDevelopment Operation Officer | |
Executive Officer Biographies
Philip Astley-Sparke | Chief Executive Officer
Please see Mr. Astley-Sparke’s biographical information under “Board of Directors — Director Biographies,” of this Proxy Statement
Robert Coffin, Ph.D.--| President and Chief ExecutiveResearch & Development Officer Please see Dr.
Coffin'sCoffin’s biographical information under
"Board“Board of
Directors—Directors — Director Biographies,
"” of this Proxy Statement.
Philip Astley-SparkeAndrea Pirzkall, M.D.--| Chief Medical Officer
Dr. Andrea Pirzkall, M.D. joined our management team in a full-time role in August 2020. Prior to joining Replimune, Dr. Pirzkall served as Executive Chairman,Director, Clinical Development at BeiGene, Ltd. from August 2017 to July 2020, where she focused on the development of anti-PD-1 and combination therapies and served on the BeiGene, Ltd./Celgene Corporation joint development committee. From September 2007 to August 2017, Dr. Pirzkall held various positions of increasing responsibility at Genentech, Inc., starting as an Assistant Medical Director and rising to become Principal Medical Director, where she led the development of several novel biologic agents. From 2002 to 2003, she served part-time as Director, Clinical Affairs at DxTx Medical, Inc., a medical device company. From 2001 to 2012, Dr. Pirzkall was an Associate Adjunct Professorship of Radiation Oncology, Radiology, and Neurosurgery at the University of California, San Francisco, where she completed a fellowship in Radiation Oncology and Medical Physics. Dr. Pirzkall obtained her M.D. from Friedrich-Schiller University and completed her residency and dissertation in Radiation Oncology at Ruprecht-Karls University & the German Cancer Research Center.
Jean Franchi| Chief Financial Officer
Ms. Jean Franchi has served as our Chief Financial Officer since December 2019. Previously, she was Chief Financial Officer at Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, from August 2017 to June 2019. From August 2015 to July 2017, she served as Chief Financial Officer, Treasurer and Secretary
at Dimension Therapeutics, Inc., a biotechnology company. From February 2012 to July 2015, Ms. Franchi served as Chief Financial Officer at Good Start Genetics, Inc., a molecular genetics information company. From 1995 to 2011, Ms. Franchi held various positions at Sanofi S.A., including Senior Vice President of Corporate Finance, Senior Vice President of Business Unit Finance, and
Treasurer Please see Mr. Astley-Sparke's biographical information under "BoardVice President of Directors—Director Biographies,"Finance and Controller, Product Line and International Group. Ms. Franchi currently serves on the boards of this Proxy Statement
directors of Biodesix, Inc., Visioneering Technologies, Inc., and Dynacure S.A. Ms. Franchi holds a B.B.A. from Hofstra University.
Colin Love, Ph.D.-- | Chief Operating Officer Dr. Colin Love, Ph.D. has served as our Chief Operating Officer since
October 2015 and has been a member of the
Boardboards of directors of Replimune Limited
and Replimune (Ireland) Ltd. since July
2017.2017 and October 2019, respectively. Following the acquisition of BioVex Group, Inc. by Amgen, Inc. in 2011, Dr. Love remained at Amgen, Inc. as Vice President of Clinical Operations, working on T-Vec until it was approved in 2015. Since 2014, Dr. Love has also provided consulting support to biotechnology companies through Clove Consulting Ltd. From 2000 until it was acquired in 2011, Dr. Love served as Senior Vice President of Product Development at BioVex Group, Inc.
Currently, Dr. Love is a member of the board of directors of Freeline Therapeutics Holdings PLC. Dr. Love received a B.Sc. in Biochemistry and a Ph.D. in Biochemistry from Glasgow University.
Pamela Esposito, Ph.D.-- | Chief Business Officer Dr. Pamela Esposito, Ph.D. has served as our Chief Business Officer since
November 2015. Previously, she was Chief Business Officer at Ra Pharmaceuticals, Inc. from 2013 to 2015. As a member of Ra Pharmaceuticals, Inc.
's’s senior management team, Dr. Esposito played a leadership role in strategy, helping Ra Pharmaceuticals, Inc. transform from a discovery platform to a clinical-stage company. Prior to Ra Pharmaceuticals, Inc., from 2010 to 2011, she was Vice President of Business Development at BioVex Group, Inc. Dr. Esposito
currently serves on the board of directors of Accent Therapeutics, Inc., a privately held company, and Kymera Therapeutics, Inc., a Nasdaq-listed company. Dr. Esposito earned a Ph.D. in Pharmacology from Tufts University School of Medicine in 2002 and a B.A. in Biochemistry/Molecular Biology from Dartmouth College.
Howard Kaufman, M.D.Sushil Patel, Ph.D.-- | Chief MedicalCommercial Officer Dr. Howard L. Kaufman
Mr. Sushil Patel joined usour management team in May 2021. Prior to joining Replimune, he served as Chief Medical OfficerVP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in September 2017. He has been the Editor-In-Chief of the Journal of Targeted Therapies in Cancer andlung cancer. From 1999 to 2002, he was Senior Consultant at Front Line Strategic Management Consulting. Prior to this served as a Senior Associate EditorResearch Executive at IMS Health in the Pharma Strategy Group from 1996 to 1999 and Clinical Research Scientist at the JournalCentral Public Health Laboratory from 1993 to 1996. He obtained his Ph.D. in Molecular Biology from the University of Translational Medicine since 2007. Most recently, Dr. Kaufman was Associate Director for Clinical ScienceLondon in 1999, his M.S. in Biotechnology from the Imperial College London in 1993, and his B.S. in Microbiology and Microbial Technology from the University of the Rutgers Cancer Institute of New Jersey from 2014 to 2017. He previously was a leading academicWarwick in the study of tumor immunotherapy and the optimization of viral vectors for the1992.
Table of Contents
treatment of cancer from 1997 to 2017. He was President of the Society for Immunotherapy of Cancer from 2014 to 2016. He previously was the Cancer Center Director and Associate Dean of Rush University Medical Center from 2009 to 2013. Dr. Kaufman has published over 400 peer-reviewed scientific papers, books, and review articles and serves on the editorial board of the Journal for Immunotherapy of Cancer. Dr. Kaufman received his Medical Degree from Loyola University in 1986, completed General Surgery residency at Boston University and fellowship training in Tumor Immunology and Surgical Oncology at the National Cancer institute.
Stephen GorgolTanya Lewis --| Chief AccountingDevelopment Operations Officer
Mr. Stephen Gorgol
Ms. Lewis has served as our Chief Accounting Officer since October 2016. Previously, Mr. Gorgol wasExecutive Vice President, FinanceChief Regulatory Officer and AdministrationQuality Officer at uniQure,Karyopharm Therapeutics Inc., a pharmaceutical company, since November 2019, and previously served as Senior Vice President, Regulatory and Quality Affairs from April 2013November 2018 to May 2016.November 2019. Prior to uniQure,joining Karyopharm Therapeutics, Ms. Lewis served as Vice President, Regulatory and Quality Affairs for Syros Pharmaceuticals, Inc., Mr. Gorgol was the Chief Financial Officera pharmaceutical company, from January 2017 to July 2018. Prior to joining Syros Pharmaceuticals, Ms. Lewis served as Vice President, Regulatory Affairs and Quality Assurance for Idera Pharmaceuticals, Inc., a pharmaceutical company, from October 2015 to December 2016. Before joining Idera Pharmaceuticals, Ms. Lewis served as Vice President, Regulatory Affairs for Tesaro, Inc., a pharmaceutical company, from October 2011 to June 2015 and prior to that served in various roles at Millennium Pharmaceuticals. Inc. Ms. Lewis holds a Bachelor of BioVex Group, Inc.Science degree in Biology from May 2005 until it was acquired by Amgen, Inc.Northeastern University and a Master of Science degree in 2011. Mr. Gorgol earned a B.S. in Accounting at the Plymouth State University in 1980.Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Allied Health Science.
Summary Compensation Table
The following table sets forth information about compensation awarded or paid to our named executive officers for the fiscal years ending March 31, 20182020 and 2019.2021.
| Name and Principal Position | | | Year
Ended | | | Base Salary
($) | | | Bonus
($) | | | Option
Awards(1)
($) | | | Non-Equity
Incentive Plan
Compensation(2)
($) | | | All Other
Compensation
($) | | | Total
($) | |
| Philip Astley-Sparke | | | | | 2021 | | | | | | 533,000 | | | | | | — | | | | | | 1,698,067 | | | | | | 226,525 | | | | | | — | | | | | | 2,457,592 | | |
Chief Executive
Officer | | | | | 2020 | | | | | | 437,754 | | | | | | — | | | | | | 1,541,213 | | | | | | 176,196 | | | | | | — | | | | | | 2,155,164 | | |
| Robert Coffin, Ph.D. | | | | | 2021 | | | | | | 533,000 | | | | | | — | | | | | | 1,698,067 | | | | | | 226,525 | | | | | | — | | | | | | 2,457,592 | | |
President and Chief Research & Development
Officer | | | | | 2020 | | | | | | 517,500 | | | | | | — | | | | | | 2,208,351 | | | | | | 208,294 | | | | | | — | | | | | | 2,934,145 | | |
Andrea Pirzkall(3) | | | | | 2021 | | | | | | 261,399 | | | | | | — | | | | | | 4,379,910 | | | | | | 85,262 | | | | | | — | | | | | | 4,726,571 | | |
| Chief Medical Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | |
Name and Principal Position | | Year | | Base Salary
($) | | Bonus
($) | | Option
Awards(1)
($) | | Non-Equity
Incentive Plan
Compensation(2)
($) | | All Other
Compensation
($) | | Total
($) | |
|---|
Robert Coffin, Ph.D. | | | 2019 | | | 477,991 | | | — | | | 1,548,750 | | | 238,996 | | | — | | | 2,265,737 | |
President, Chief Executive | | | 2018 | | | 389,478 | | | — | | | 592,000 | | | 146,817 | | | — | | | 1,128,295 | |
Officer and Director | | | | | | | | | | | | | | | | | | | | | | |
Philip Astley-Sparke | | | 2019 | | | 382,393 | | | — | | | 1,239,000 | | | 191,198 | | | — | | | 1,812,591 | |
Executive Chairman, Treasurer, | | | 2018 | | | 254,687 | | | — | | | 166,500 | | | 83,765 | | | — | | | 504,952 | |
Secretary and Director | | | | | | | | | | | | | | | | | | | | | | |
Howard Kaufman, M.D.(3) | | | 2019 | | | 406,000 | | | — | | | 1,327,500 | | | 142,100 | | | — | | | 1,875,600 | |
Chief Scientific Officer | | | | | | | | | | | | | | | | | | | | | | |
Colin Love, Ph.D. | | | 2019 | | | 310,641 | (4) | | — | | | 885,000 | | | 108,725 | (4) | | — | | | 1,304,366 | |
Chief Operating Officer | | | 2018 | | | 311,834 | (4) | | — | | | 277,500 | | | 101,784 | (4) | | — | | | 691,118 | |
(1)(1)- The amounts reported in this column reflect the full grant date fair value for awards granted during each of the fiscal years ended March 31,
20182020 and 2019.2021. The grant date fair value was computed in accordance with Accounting Standards Codification Topic 718,Compensation—Compensation — Stock Compensation. The assumptions we used in valuing options are described in Note 109 to our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended March 31, 2019.2021.
(2)
(2)The amounts reported in this column represent bonuses based upon the achievement of company and individual performance objectives relative to the target company and individual goals for each of the fiscal years ended March 31, 20182020 and 2019. We2021, which were paid such bonuses in April 20192020 and April 2018,2021, respectively.
(3)
(3)Dr. Kaufman was not one of ourNot a named executive officersofficer for the fiscal year ended March 31, 2018.
(4)Amounts presented for Dr. Love for2020. Ms. Pirzkall joined the Company as its full-time Chief Medical Officer on August 31, 2020. The reported compensation reflects payments actually received during the fiscal yearsyear ended March 31, 2018 and 2019 are based on an assumed conversion ratio of British pounds to dollars of 1.4015 and 1.302344, which were the exchange rates in effect as of March 31, 2018 and 2019, respectively.2021.
Our executive compensation philosophy is to generally provide compensation and benefit levels that will attract, retain, motivate and reward a highly talented executive team within the context of responsible cost management; establish a direct link between our individual/team performance and results and our executives'executives’ compensation; and align the interests and objectives of our executives with those of our stockholders by linking executive equity awards to stockholder value creation. The compensation philosophy for our executive officers is composed primarily of the following three main components: base salary, annual cash incentives and long-term equity incentives. In 2018, asAs part of our annual evaluation of executive compensation, we have engaged Pearl Meyer, an independent executive compensation consultant, to provide advice and recommendations relating to our executive officer compensation arrangements. Pearl Meyer previously provided us with guidance on executive officer compensation in connection with our initial public offering. Pearl Meyer assisted the Compensation Committee in evaluating the Company'sour executive officer compensation for alignment with governance and market best practices, and to provide recommendations on the appropriate compensation philosophy to guide the Compensation Committee in determining executive officer compensation.
The base salaries for the fiscal year ended March 31, 2019,2021 were determined for each named executive officer by the Board or the Compensation Committee, each of which givesgave consideration to each officer'sofficer’s experience, expertise and performance, as well as market compensation levels for similar positions.
| Name | | | Base
Salary ($)(1) | |
Philip Astley-Sparke, Chief Executive Officer | | | | | 533,000 | | |
Robert Coffin, Ph.D., President and Chief Research & Development Officer | | | | | 533,000 | | |
Andrea Pirzkall, Chief Medical Officer | | | | | 261,399 | | |
(1)
The
reported base salaries
set forth below take into account an increase of each named executive officer's base salary in connection withreflect payments actually received during our
initial public offering. | | | | |
Name | | Base
Salary ($) | |
|---|
Robert Coffin, Ph.D.,President, Chief Executive Officer and Director | | | 477,991 | |
Philip Astley-Sparke,Executive Chairman, Treasurer, Secretary and Director | | | 382,393 | |
Howard Kaufman, M.D.,Chief Scientific Officer | | | 406,000 | |
Colin Love, Ph.D.,Chief Operating Officer | | | 310,641 | (1) |
(1)Amount presented for Dr. Love is based on an assumed conversion ratio of British pounds to dollars of 1.302344, which was the exchange rate in effect as offiscal year ended March 31, 2019.
2021.
Annual Performance-Based Incentive Opportunity In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash incentives, which are designed to motivate our executives to achieve defined annual corporate goals and to reward our executives for their contributions towards the achievement of these goals. The annual performance-based incentive each named executive officer was eligible to receive in
respect of services performed during the fiscal year ended March 31,
20192021 was
generallydetermined at the discretion of the Board and Compensation Committee based
in part on the extent to which the officer achieved the corporate goals and individual objectives that our Board established at the beginning of the fiscal
year and then again after our initial public offering.year. After the end of the fiscal year ended March 31,
2019,2021, our Board reviewed performance against each goal and objective and determined the extent to which each goal and objective was
achieved. Inachieved, recognizing such achievements were delivered within a challenging COVID-19 environment.
For our fiscal year ended March 31, 2019,2021, Mr. Astley-Sparke and Dr. Coffin and Mr. Astley-Sparke were eligible to receive a target bonus of up to 50% of their respective base salary, while each of Dr. Love, and Dr. KaufmanMs. Pirzkall was eligible to receive a target bonus of up to 35%40% of their respectiveher base salary. Our Board reviewed the corporate goals for the fiscal year ended March 31, 20192021 and the individual objectives of each named executive officer and determined that on an overall basis, significantin light of the challenging COVID-19 environment, progress had been made towards achieving allcertain of those goals. In recognition of theseRecognizing the achievements and the efforts of each executive, the committee awarded each of our named executive officers and the Company’s overall performance in the context of the broader challenges presented by the COVID-19 pandemic, the Compensation Committee made the decision to award each such officer eligible for performance bonuses 100%85.0% of their target bonus opportunity for the fiscal year ended March 31, 2019. For2021. Accordingly, for the fiscal year ended March 31, 2019,2021, Mr. Astley-Sparke and Dr. Coffin Mr. Astley-Sparke, Dr. Kaufman and Dr. Love were paid cash bonuses of $238,996, $191,198, $142,100$226,525 each, and $108,725, respectively. The foregoing amountMs. Pirzkall was paid a cash bonus of the bonus paid to Dr. Love is based on an assumed conversion ratio of British pounds to dollars of 1.302344, which was the exchange rate in effect as of March 31, 2019.$85,262.
Table of Contents
Outstanding Equity Awards at Fiscal Year End
The following table provides information about outstanding equity awards held by each of our named executive officers at March 31,
2019.2021.
| | | | Option Awards(1) | |
| Name | | | Number of Securities
Underlying Unexercised
Options (#)
Exercisable | | | Number of Securities
Underlying Unexercised
Options (#) Unexercisable | | | Option
Exercise
Price ($) | | | Option
Expiration
Date | |
| Philip Astley-Sparke | | | | | 82,060 | | | | | | 7,461(2) | | | | | | 3.30 | | | | | | 7/26/2027 | | |
| | | | | | 93,320 | | | | | | 46,680(3) | | | | | | 15.00 | | | | | | 7/19/2028 | | |
| | | | | | 73,330 | | | | | | 79,720(4) | | | | | | 15.50 | | | | | | 4/1/2029 | | |
| | | | | | — | | | | | | 265,000(5) | | | | | | 9.78 | | | | | | 4/1/2030 | | |
| Robert Coffin, Ph.D. | | | | | 291,734 | | | | | | 26,565(2) | | | | | | 3.30 | | | | | | 7/26/2027 | | |
| | | | | | | | | | | |
| | Option Awards(1) |
|---|
Name | | Number of Securities
Underlying Unexercised
Options (#)
Exercisable | | Number of Securities
Underlying Unexercised
Options (#) Unexercisable | | Option
Exercise
Price ($) | | Option
Expiration
Date |
|---|
Robert Coffin, Ph.D. | | | 132,614 | | | 185,685 | (2) | | 3.30 | | 7/26/2027 |
| | | — | | | 175,000 | (3) | | 15.00 | | 7/19/2028 |
Philip Astley-Sparke | | | 37,300 | | | 52,221 | (2) | | 3.30 | | 7/26/2027 |
| | | — | | | 140,000 | (3) | | 15.00 | | 7/19/2028 |
Howard Kaufman, M.D. | | | 55,942 | | | 93,260 | (2) | | 3.30 | | 9/1/2027 |
| | | — | | | 150,000 | (3) | | 15.00 | | 7/19/2028 |
Colin Love, Ph.D. | | | 62,164 | | | 87,039 | (2) | | 3.30 | | 7/26/2027 |
| | | — | | | 100,000 | (3) | | 15.00 | | 7/19/2028 |
| | | | Option Awards(1) | |
| Name | | | Number of Securities
Underlying Unexercised
Options (#)
Exercisable | | | Number of Securities
Underlying Unexercised
Options (#) Unexercisable | | | Option
Exercise
Price ($) | | | Option
Expiration
Date | |
| | | | | | 116,650 | | | | | | 58,350(3) | | | | | | 15.00 | | | | | | 7/19/2028 | | |
| | | | | | 105,073 | | | | | | 114,227(4) | | | | | | 15.50 | | | | | | 4/1/2029 | | |
| | | | | | — | | | | | | 265,000(5) | | | | | | 9.78 | | | | | | 4/1/2030 | | |
| Andrea Pirzkall | | | | | — | | | | | | 300,000(6) | | | | | | 22.45 | | | | | | 7/20/2030 | | |
(1)
Upon an option holder'sholder’s termination of employment on account of the option holder'sholder’s death or disability, these options expire on the first anniversary of the option holder'sholder’s termination. If an option holder'sholder’s employment terminates for any other reason, these options expire three months after the option holder'sholder’s termination.
(2)
(2)25% of the shares underlying this stock option vested on July 26, 2018 and the remainder of the shares underlying this stock option vested and will continue to vest in approximately equal monthly installments thereafter until July 26, 2020.2021.
(3)
(3)25% of the shares underlying this stock option vested on July 19, 20182019 and the remainder of the shares underlying this stock option vested and will continue to vest in 24 approximately equal monthly installments thereafter.thereafter until July 19, 2022
25% of the shares underlying this stock option vested on April 1, 2020 and the remainder of the shares underlying this stock option vested and will continue to vest in approximately equal monthly installments thereafter until April 1, 2023.
(5)
25% of the shares underlying this stock option vested on April 1, 2021 and the remainder of the shares underlying this stock option vested and will continue to vest in approximately equal monthly installments thereafter until April 1, 2024.
(6)
25% of the shares underlying this stock option vest on July 20, 2021 and the remainder of the shares underlying this stock option will continue to vest in approximately equal monthly installments thereafter until July 20, 2024.
Our named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan during the fiscal year ended March 31,
2019,2021, other than pursuant to the plans described under
"401(k) Plan" and "U.K. Pension Contribution“401(k) Plan.
"”
Nonqualified Deferred Compensation Our named executive officers did not participate in, or earn any benefits under, a nonqualified defined contribution or other nonqualified deferred compensation plan during the fiscal year ended March 31,
2019.2021.
We offer a tax-qualified retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation up to certain statutory limits, which are updated annually. We provide matching contributions up to 50% of actual dollars contributed, not to exceed a maximum of 8% of gross salary. Employee contributions are allocated to each
participant'sparticipant’s individual account and are then invested in selected investment alternatives according to the
participant'sparticipant’s directions. Employees are immediately and fully vested in their own
contributions, but any contributions we make vest ratably over the first five years of service. After five years of service, contributions we make vest 100%.and in our matching contributions. The 401(k) plan is intended to be qualified under Section 401(a) of the Internal Revenue Code, or the Code, with the related trust intended to be tax exempt under Section 501(a) of the Code. As a tax-qualified retirement
Table of Contents
plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are not taxable to the employees until withdrawn or distributed from the 401(k) plan.
U.K. Pension Contribution Plan
We provide a
"stakeholder"“stakeholder” pension contribution plan for our employees in the United Kingdom, pursuant to which we match our
employees'employees’ contributions each year in amounts up to 8% of their annual base salary.
Set forth below are descriptions of the employment agreements that we have entered into with each of our named executive officers, including descriptions of our named executive
officers'officers’ base salary, target annual bonus opportunity and standard benefit plan participation.
Philip Astley-Sparke
Effective as of October 1, 2015, Replimune, Inc. entered into an employment agreement with Mr. Astley-Sparke. Under Mr. Astley-Sparke’s employment agreement, he is entitled to a base salary and is eligible to receive an annual target performance bonus based on a percentage of his base salary, each as determined and may be adjusted by the Compensation Committee. Mr. Astley-Sparke is eligible to participate in our employee benefit plans, practices and programs on a basis which is no less favorable than is provided to our other similarly situated executives.
Mr. Astley-Sparke’s employment agreement further provides that in the event his employment is terminated without “cause,” as defined in his employment agreement, or he terminates his employment for “good reason,” as defined in his employment agreement, and subject to customary conditions, including his execution of an acceptable release, Mr. Astley-Sparke is entitled to receive 12 months of base salary and monthly cash payments equal to the costs of COBRA health continuation for the earlier of six months or until Mr. Astley-Sparke becomes eligible under another employer’s group coverage.
In addition, in the event of a change in control of our business, if, within 24 months following such change of control, Mr. Astley-Sparke is terminated without “cause” or he has terminated his employment for “good reason,” Mr. Astley-Sparke will be entitled to receive any accrued but unpaid compensation, together with a lump sum payment equal to the sum of Mr. Astley-Sparke’s then current annual base salary or, if greater, the base salary for the year immediately preceding, subject to customary conditions, including his execution of an acceptable release. If an excise tax under Section 4999 of the Code is imposed on the payments and benefits payable to Mr. Astley-Sparke in connection with a change in control, Mr. Astley-Sparke will be entitled to a tax gross-up payment for such excise taxes.
Effective as of October 1, 2015, Replimune, Inc. entered into an employment agreement with Dr.
Coffin for the position of Chief Executive Officer of Replimune.Coffin. Under Dr.
Coffin'sCoffin’s employment agreement, he is entitled to a base salary and is eligible to receive an annual target performance bonus based on a percentage of his base salary, each as determined and may be adjusted by the Compensation Committee. Dr. Coffin is eligible to participate in our employee benefit plans, practices and programs on a basis which is no less favorable than is provided to our other similarly situated executives.
Dr.
Coffin'sCoffin’s employment agreement further provides that in the event his employment is terminated without
"cause,"“cause,” as defined in his employment agreement, or he terminates his employment for
"good“good reason,
"” as defined in his employment agreement, and subject to customary conditions, including his execution of an acceptable release, Dr. Coffin is entitled to receive 12 months of base salary and monthly cash payments equal to the costs of COBRA health continuation for the earlier of six months or until Dr. Coffin becomes eligible under another
employer'semployer’s group coverage.
In addition, in the event of a change in control of our business, if, within 24 months following such change of control, Dr. Coffin is terminated without "cause"“cause” or he has terminated his employment for "good“good reason,"” Dr. Coffin will be entitled to receive any accrued but unpaid compensation, together with a lump sum payment equal to the sum of Dr. Coffin'sCoffin’s then current annual base salary or, if greater, the base salary for the year immediately preceding, subject to customary conditions, including his execution of an acceptable
release. If an excise tax under Section 4999 of the Code is imposed on the payments and benefits payable to Dr. Coffin in connection with a change in control, Dr. Coffin will be entitled to a tax gross-up payment for such excise taxes.
Philip Astley-SparkeAndrea Pirzkall Effective as of October 1, 2015, Replimune, Inc.
On May 22, 2020, Dr. Pirzkall entered into an employment agreement with
Mr. Astley-Sparke for the position of Executive Chairman of Replimune. Mr. Astley-Sparke currently spends 80% of his time working for Replimune.Replimune, Inc. Under
Mr. Astley-Sparke'sDr. Pirzkall’s employment agreement,
heshe is entitled to
aan initial base salary
of $425,000 and is eligible to receive an annual
discretionary target performance bonus based on a percentage of
hisher base salary,
each as determinedwhich such percentage is initially 40%. Each of her salary and
her discretionary bonus may be adjusted by the Compensation Committee.
Mr. Astley-Sparke is eligibleDr. Pirzkall’s employment agreement also provides for customary terms of benefits afforded to Dr. Pirzkall, including the ability to participate in
our employee benefitvarious group insurance plans,
practicesreimbursement for necessary and
programs on a basis which is no less favorable than is provided to our other similarly situated executives. Mr. Astley-Sparke'sreasonable business expenses and paid time off.
Dr. Pirzkall’s employment agreement further provides that in the event
hisher employment is terminated without
"cause,"“cause,” or she terminates her employment for “good reason,” each, as defined in
his employment agreement, or he terminates his employment
Table of Contents
for "good reason," as defined in hisher employment agreement, and subject to customary conditions, including hisher execution of an acceptable release, Mr. Astley-Sparke is entitled to receive 12 months of base salary and monthly cash payments equal to the costs of COBRA health continuation for the earlier of six months or until Mr. Astley-Sparke becomes eligible under another employer's group coverage.
In addition, in the event of a change in control of our business, if, within 24 months following such change of control, Mr. Astley-Sparke is terminated without "cause" or he has terminated his employment for "good reason," Mr. Astley-Sparke will be entitled to receive any accrued but unpaid compensation, together with a lump sum payment equal to the sum of Mr. Astley-Sparke's then current annual base salary or, if greater, the base salary for the year immediately preceding, subject to customary conditions, including his execution of an acceptable release. If an excise tax under Section 4999 of the Code is imposed on the payments and benefits payable to Mr. Astley-Sparke in connection with a change in control, Mr. Astley-Sparke will be entitled to a tax gross-up payment for such excise taxes.
Effective as of June 22, 2018, Replimune, Inc. entered into an employment agreement with Dr. Kaufman for the position of Chief Medical Officer of Replimune. Under Dr. Kaufman's employment agreement, he is entitled to a base salary and is eligible to receive an annual target performance bonus based on a percentage of his base salary, each as determined and may be adjusted by the Compensation Committee. Dr. Kaufman is eligible to participate in our employee benefit plans, practices and programs on a basis which is no less favorable than is provided to our other similarly situated executives.
Dr. Kaufman's employment agreement further provides that in the event his employment is terminated without "cause," as defined in his employment agreement, or he terminates his employment for "good reason," as defined in his employment agreement, and subject to customary conditions, including his execution of an acceptable release, Dr. KaufmanMs. Pirzkall is entitled to receive an amount equal to 0.75 times histhree quarters of her annual base salary paid in installments over a 9-monthnine-month period, and reimbursement on a lump-sum cash payment equal tomonthly basis for the COBRA premiums that he would pay if he electedDr. Pirzkall pays for continued health care coverage under Replimune’s group health plans for herself and her dependents until the Company's health planearlier of nine months, until Dr. Pirzkall becomes eligible under another employer’s group coverage, or until Dr. Pirzkall ceases to be eligible for the 9-month period following his termination.
COBRA coverage for any reason.
In addition, in the event of a change in control of our business, if, within 12 months following such change of control, Dr.
KaufmanPirzkall is terminated without
"cause"“cause” or
heshe has terminated
hisher employment for
"good“good reason,
"” Dr.
KaufmanPirzkall will be entitled to receive any accrued but unpaid compensation,
together an amount equal to
hisher annual base salary and target bonus for the year of termination paid in monthly installments over a 12-month period, and
a lump-sum payment equalmonthly COBRA premium reimbursement until the earliest to
occur of the
COBRA premiums he would pay if he elected continued health coverage underend of the
Company's health plan for the 12-monthtwelve-month period following
hisDr. Pirzkall’s termination
subject to customary conditions, including his execution of an acceptable release. Effectiveand a disqualifying event, as of September 16, 2015, Replimune Limited entered into andefined in her employment agreement with Dr. Love foragreement.
Further, the
position of Chief Operating Officer of Replimune. Under Dr. Love's employment agreement
he is entitled to a base salary and is eligible to receive an annual target performance bonus based on a percentage of his base salary, each as determined and may be adjusted by the Compensation Committee. Dr. Love is eligible to participate in our employee benefit plans, practices and programs. Dr. Love's employment agreement further provides that, in the event he is terminated,that Dr. Love may bePirzkall becomes entitled to receive payment in lieupayments that constitute “excess parachute payments” within the meaning of receiving six months' noticeSection 280G of termination in an amount
Tablethe Internal Revenue Code of Contents
equal1986, as amended, the aggregate present value of such payments will be reduced only if such reduction will provide Dr. Pirzkall with a greater net after-tax benefit than would no reduction.
Pursuant to
his base salary, as at the date of termination, which he would have been entitled to receive during the six-month notice period, less income tax and National Insurance contributions, andher employment agreement, Dr. Pirzkall is subject to customary
conditions.non-competition and non-solicitation covenants during the term of her employment and for a period of one year thereafter. Dr. Love's employment agreement further provides that in the event his employmentPirzkall is terminated without "cause," as defined in his employment agreement, or he terminates his employment for "good reason," as defined in his employment agreement, Dr. Love is entitled to be paid a sum equal to twelve months of his "fixed annual salary," as defined in his employment agreement, less any "payment in lieu," payable in twelve equal monthly installments following his termination.
In addition, in the event of a change in control of our business, if, within twenty-four months following such change in control, Dr. Love is terminated without "cause" or he has terminated his employment for "good reason," Dr. Love will be entitled to receive a sum equal to twelve months of his "fixed annual salary," less any "payment in lieu," payable within thirty days following his termination.
Pursuant to their employment agreements, our named executive officers arealso subject to standard covenants ofcustomary confidentiality and nondisclosure, assignment of intellectual property work product and post-termination noncompetition and non-solicitation of employees, consultants and customers.
restriction.
In connection with our executive compensation review
during the fiscal year ended March 31, 2021, our Compensation Committee
engagedcontinued to rely on Pearl Meyer to provide our Compensation Committee
with guidance with respect to the development and implementation of our compensation arrangements with our executive officers and other employees.
Our Compensation Committee charter requires that itsthe compensation consultant be independent of Replimuneour management. During the fiscal year ended March 31, 2019,2021, Pearl Meyer did not provide services to us other than the services described in this Proxy Statement. Our Compensation Committee has determined that Pearl Meyer is independent and that its work does not raise any conflict of interest.
The report of the Audit Committee is not "soliciting“soliciting material,"” is not deemed "filed"“filed” with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, both as amended. The Audit Committee has reviewed
Replimune'sReplimune’s audited consolidated financial statements for the year ended March 31,
20192021 and has discussed these statements with management and PricewaterhouseCoopers LLP, or PwC,
the Company'sReplimune’s independent registered public accounting firm.
ReplimuneReplimune’s management
team is responsible for the preparation of
the Company'sReplimune’s financial statements and for maintaining an adequate system of disclosure controls and procedures and internal control over financial reporting for that purpose. The independent registered public accounting firm audits the annual consolidated financial statements prepared by management, expresses an opinion as to whether those consolidated financial statements present fairly the consolidated financial position, results of operations and cash flows of Replimune in conformity with U.S. generally accepted accounting principles and discusses any issues they believe should be raised with
us.the Audit Committee. The Audit Committee is responsible for providing independent, objective oversight of
the Company'sReplimune’s accounting functions and internal controls.
The Audit Committee also received from, and discussed with, PwC the written disclosures and other communications that
the Company'sReplimune’s independent registered public accounting firm is required to provide to the Audit Committee, including the matters required to be discussed by Statement on Auditing Standards No. 1301, as amended (Communications with Audit Committees), as adopted by the Public Company Accounting Oversight Board, or PCAOB, in Rule 3200T.
PwC also provided the Audit Committee with the written disclosures and the letter required by the PCAOB requiring independent registered public accounting firms to annually disclose in writing all relationships that, in their professional opinion, may reasonably be thought to bear on independence, to confirm their perceived independence and to engage in a discussion of independence. The Audit Committee has reviewed this disclosure and has discussed with PwC their independence from Replimune.
Based on its discussions with management and ourReplimune’s independent registered public accounting firm as outlined above, and its review of the representations and information provided by management and ourReplimune’s independent registered public accounting firm, the Audit Committee recommended to the Board that the audited consolidated financial statements be included in the ReplimuneReplimune’s Annual Report on Form 10-K for the year ended March 31, 2019,2021, for filing with the Securities and Exchange Commission.
Respectfully submitted by the Audit Committee,
Joseph Slattery, Chairperson
Kapil Dhingra
Dieter Weinand
| | |
Respectfully submitted by the Audit Committee, | | |
Joseph Slattery,Chair
Kapil Dhingra
Dieter Weinand |
|
|
28
Table of Contents
PROPOSAL NO. 2—AMENDMENT OF CERTIFICATE OF INCORPORATION
We are asking our stockholders to approve an amendment (the "Amendment") of our certificate of incorporation. The following description is a summary only and is qualified in its entirety by reference to the complete text of the Amendment appended to this Proxy Statement asAppendix A, which we encourage our stockholders to read in its entirety.
The Amendment would amend and restate Article Eleven of our certificate of incorporation. Currently, Article Eleven, Section 2 provides that, unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. On December 19, 2018, the Chancery Court of Delaware ruled that such exclusive federal forum provisions are invalid under Delaware law. Additionally, the Amendment would provide that the Delaware exclusive forum provision set forth therein will not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, or the respective rules and regulations promulgated thereunder, or otherwise limit the rights of any stockholder to bring any claim under such laws, rules or regulations in any United States federal district court of competent jurisdiction. The Board unanimously approved, and recommends that our stockholders approve, the Amendment to amend and restate Article Eleven.
The affirmative vote of at least seventy-five percent (75%) of the outstanding shares of our capital stock present in person or represented by proxy at the 2019 Annual Meeting and entitled to vote is required to approve the Amendment. An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote "against" the Amendment. Broker non-votes will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the proposal.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE AMENDMENT OF OUR CERTIFICATE OF INCORPORATION.
(PROPOSAL NO. 2 ON YOUR PROXY CARD)
Table of Contents
PROPOSAL NO. 3—— RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
We are asking our stockholders to ratify the Audit
Committee'sCommittee’s selection of PricewaterhouseCoopers LLP, or PwC, as our independent registered public accounting firm for the fiscal year ending March 31,
2020.2022. PwC has served as our independent registered public accounting firm since 2018.
The Audit Committee annually reviews the independent registered public accounting
firm'sfirm’s independence, including reviewing all relationships between the independent registered public accounting firm and us and any disclosed relationships or services that may impact the objectivity and independence of the independent registered public accounting firm, and the independent registered public accounting
firm'sfirm’s performance.
Although stockholder ratification is not required by our bylaws or otherwise, the Board believes it is advisable to provide stockholders an opportunity to ratify this selection and is submitting the selection of PwC
as our independent registered public accounting firm to our stockholders for ratification as a matter of good corporate practice. If the selection is not ratified, the Audit Committee will consider whether it is appropriate to select another independent registered public accounting firm, but is not required to do so. Even if the selection is ratified, the Audit Committee in its discretion may select a different registered public accounting firm at any time during the year if the Audit Committee determines that such a change would be in the best interests of Replimune and its stockholders.
We expect that a representative of PwC will
virtually attend the
2019 Annual Meeting and will have an opportunity to make a statement if he or she so chooses and will be available to respond to appropriate questions from
stockholders.stockholders in accordance with the Annual Meeting’s Rules of Conduct.
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm
The Audit Committee pre-approves all auditing services, and permitted non-audit services (including the fees and terms thereof) to be performed by PwC, subject to the de minimis exception for non-audit services that are approved by the Audit Committee prior to the completion of an audit. The Audit Committee may delegate pre-approval authority to one or more members of the Audit Committee consistent with applicable law, Nasdaq listing standards and SEC rules and regulations, provided that the decisions of such Audit Committee member or members must be presented to the full Audit Committee at its next scheduled meeting.
Principal Accountant Fees and Services
We regularly review the services and fees of our independent accountants. These services and fees are also reviewed by the Audit Committee on an annual basis. The approximate aggregate fees billed for the fiscal years ended March 31, 20182020 and 20192021 for each of the following categories of services are as follows:
| Fee Category | | | 2020 | | | 2021 | |
| Audit Fees | | | | $ | 879,000 | | | | | $ | 962,000 | | |
| Audit Related Fees | | | | | — | | | | | | — | | |
| Tax Fees | | | | | 33,000 | | | | | | 36,000 | | |
| All Other Fees | | | | | 1,000 | | | | | | 1,000 | | |
| Total Fees | | | | $ | 913,000 | | | | | $ | 999,000 | | |
| | | | | | | |
Fee Category | | 2018 | | 2019 | |
|---|
Audit Fees | | $ | 1,086,500 | | $ | 1,299,000 | |
Audit Related Fees | | | — | | | — | |
Tax Fees | | | 29,400 | | | 47,800 | |
All Other Fees | | | 5,000 | | | — | |
| | | | | | | | |
Total Fees | | $ | 1,120,900 | | $ | 1,346,800 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Table of Contents
Audit Fees. Consist of aggregate fees for professional services provided in connection with the annual audit of our consolidated financial statements, the review of our quarterly condensed consolidated financial statements, services in connection with our initial public offering that was completed in July 2018, consultations on accounting matters directly related to the audit, and comfort letters, consents and assistance with and review of documents filed with the SEC.
Audit-Related Fees. Consist of aggregate fees for accounting consultations and other services that were reasonably related to the performance of audits or reviews of our consolidated financial statements and were not reported above under "Audit“Audit Fees."”
Tax Fees. Consist of aggregate fees for tax compliance, tax advice and tax planning services including the review and preparation of our federal and state income tax returns. All Other Fees. Consist of aggregate fees billed for products and services provided by the independent registered public accounting firm other than those fees disclosed above. The Audit Committee pre-approved all services performed since the pre-approval policy was adopted.
The affirmative vote of a majority of shares of our common stock present
in person or represented by proxy at the
2019 Annual Meeting and entitled to vote is required to ratify the selection of our independent
auditors.registered public accounting firm. An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote
"against"“against” the ratification of the
selection of our independent
auditors.registered public accounting firm. Because the ratification of the
selection of our independent
auditorsregistered public accounting firm is a routine matter, a nominee holding shares in street name may vote on this proposal in the absence of instructions from the beneficial owner.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR"“FOR” THE RATIFICATION OF THE APPOINTMENTSELECTION OF PWC AS THE COMPANY'SREPLIMUNE’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. (PROPOSAL NO. 3 ON YOUR PROXY CARD)2)
BENEFICIAL OWNERSHIP OF COMMON STOCK
The following table sets forth information regarding the beneficial ownership of our common stock as of June 30,
20192021 (unless otherwise specified) by:
•
each of our directors and named executive officers;
•
•all of our directors and executive officers as a group; and
•
•each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.
Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including options,
pre-funded warrants, warrants and
warrantscertain other derivative securities that are currently exercisable,
will become exercisable, or
exercisableare currently vested, or will become vested, in each case, within 60 days after June 30,
2019.2021. Shares of our common stock issuable pursuant to
stock options,
pre-funded warrants, warrants and
warrantscertain other derivative securities are deemed outstanding for
purposes of computing the percentage of the person holding such options,
pre-funded warrants, warrants or
warrantsother derivate securities and the percentage of any group of which the person is a member, but are not deemed outstanding for computing the percentage of any other person.
Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Section 13(d) and 13(g) of the Securities Act. As of June 30,
2019,2021, there were
31,666,18246,730,451 shares of
Table of Contents
our common stock outstanding. Unless otherwise indicated, the address for each beneficial owner is c/o Replimune Group, Inc., 18 Commerce Way,500 Unicorn Park, Woburn, MA 01801.
| Beneficial Owner | | | Number of Shares
Beneficially Owned† | | | Percentage of Shares
Beneficially Owned (%) | |
| Greater than 5% Stockholders: | | | | | | | | | | | | | |
Entities affiliated with Atlas Ventures(1) | | | | | 3,229,912 | | | | | | 6.9% | | |
FMR LLC(2) | | | | | 2,626,417 | | | | | | 5.6% | | |
Forbion Capital Fund III Coöperatief U.A(3) | | | | | 5,115,121 | | | | | | 10.9% | | |
Omega Fund IV, L.P.(4) | | | | | 5,256,917 | | | | | | 11.2% | | |
Redmile Group, LLC(5) | | | | | 4,743,286 | | | | | | 9.99% | | |
T. Rowe Price Associates, Inc.(6) | | | | | 2,625,691 | | | | | | 5.6% | | |
| Named Executive Officers, Directors and Director Nominees | | | | | | | | | | | | | |
Philip Astley-Sparke(7) | | | | | 1,630,318 | | | | | | 3.5% | | |
Robert Coffin(8) | | | | | 2,376,046 | | | | | | 5.0% | | |
Andrea Pirzkall(9) | | | | | 82,250 | | | | | | * | | |
Kapil Dhingra(10) | | | | | 158,710 | | | | | | * | | |
Hyam Levitsky(11) | | | | | 57,000 | | | | | | * | | |
Paolo Pucci(12) | | | | | 12,374 | | | | | | * | | |
Jason Rhodes(13)(1) | | | | | 3,273,412 | | | | | | 7.0% | | |
Joseph Slattery(14) | | | | | 81,298 | | | | | | * | | |
Sander Slootweg(15)(3) | | | | | 5,158,621 | | | | | | 11.0% | | |
Otello Stampacchia(16)(4) | | | | | 5,300,417 | | | | | | 11.3% | | |
Dieter Weinand(17) | | | | | 62,500 | | | | | | * | | |
All executive officers, directors and director nominees as a group (16) persons)(18) | | | | | 19,956,687 | | | | | | 40.3% | | |
| | | | | | | |
Beneficial Owner | | Number of Shares
Beneficially Owned† | | Percentage of Shares
Beneficially Owned (%) | |
|---|
Greater than 5% Stockholders: | | | | | | | |
Omega Fund IV, L.P.(1) | | | 5,103,455 | | | 16.1 | % |
Forbion Capital Fund III Coöperatief U.A.(2) | | | 4,970,121 | | | 15.7 | % |
Atlas Venture Fund X, L.P.(3) | | | 3,822,313 | | | 12.1 | % |
Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP(4) | | | 2,838,968 | | | 9.0 | % |
Redmile Group, LLC(5) | | | 2,188,956 | | | 6.9 | % |
Foresite Capital Fund III, L.P. and Foresite Capital Fund IV, L.P.(6) | | | 2,009,312 | | | 6.3 | % |
Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS LP(7) | | | 1,606,817 | | | 5.1 | % |
Directors and Named Executive Officers: | | | | | | | |
Robert Coffin(8) | | | 2,625,277 | | | 8.2 | % |
Philip Astley-Sparke(9) | | | 1,526,838 | | | 4.8 | % |
Howard Kaufman(10) | | | 112,102 | | | * | |
Colin Love(11) | | | 1,223,811 | | | 3.9 | % |
Jason Rhodes(12)(3) | | | 4,457,182 | | | 14.1 | % |
Sander Slootweg(13)(2) | | | 4,973,917 | | | 15.7 | % |
Otello Stampacchia(14)(1) | | | 5,107,251 | | | 16.1 | % |
Kapil Dhingra(15) | | | 159,006 | | | * | |
Hyam Levitsky(16) | | | 7,593 | | | * | |
Joseph Slattery(17) | | | 24,133 | | | * | |
Dieter Weinand(18) | | | 7,593 | | | * | |
All directors and executive officers as a group (13 persons)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) | | | 20,713,955 | | | 63.18 | % |
**- Represents beneficial ownership of less than 1%.
†
†None of the shares are pledged as security.
(1)
Based solelyupon information contained in reports filed with the SEC pursuant to Section 16 and 13D of the Exchange Act by Atlas Venture Fund X, L.P. (“Atlas X”), Atlas Venture Associates X, L.P. (“AVA X LP”), Atlas Venture Associates X, LLC (“AVA X LLC” and, together with Atlas X and AVA X LP, the “Fund X Reporting Persons”), Atlas Venture Opportunity Fund I, L.P. (“AVOF”), Atlas Venture Associates Opportunity I, L.P. (“AVOF LP”), and Atlas Venture Associates Opportunity I, LLC (“AVOF LLC” and together with AVOF and AVOF LP, the “Opportunity Fund Reporting Persons”). Consists of (i) 2,263,627 shares of our common stock held of record by Atlas X, (ii) 19,285 shares of our common stock held by AVA X LP and (iii) 947,000 shares of our common stock held by AVOF.
AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X and AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by AVA X LP. Peter Barrett, Bruce Booth, Jean Francois Formela, Jeff Fagnan, Chris Lynch and Ryan Moore are the members of AVA LLC and collectively make investment decisions on behalf of Atlas X.
AVAO LP is the general partner of AVOF and AVOF LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AFOF LLC and AVOF LP share voting and dispositive power with respect to the shares held by AVOF. Bruce Booth, Jean-Francois Formela, David Grayzel, Jason Rhodes, and Kevin Bitterman are the members of AVAO LLC and collectively make investment decisions on behalf of AVOF.
The Fund X Reporting Persons and the Opportunity Fund Reporting Persons (collectively the “Atlas Reporting Persons”) are under common control and as a result, the Atlas Reporting Persons may be deemed to be members of a group. However, the Atlas Reporting Persons disclaim such group membership, and this disclosure shall not be deemed an admission that the Atlas Reporting Persons are members of a group for purposes of Section 13 or for any other purposes. Additionally, Jason Rhodes is a member of our board of directors. Mr. Rhodes disclaims beneficial ownership of the shares listed, except to the extent of his pecuniary interest therein. The mailing address of Atlas X and AVOF is 400 Technology Square, 10th Floor, Cambridge, MA 02139.
(2)
Based on a Schedule 13G filed with the SEC on February 13, 2019,8, 2021 by FMR LLC, FMR LLC beneficially owns 2,626,417 shares of our common stock. FMR LLC has sole voting and sole dispositive power over 275,079 and 2,626,417 shares of our common stock, respectively. The Address of FMR LLC is 245 Summer Street, Boston, Massachusetts 02210.
(3)
Based solely on a Schedule 13G/A filed with the SEC on February 16, 2021 by Forbion Capital Fund III Coöperatief U.A. (“Forbion III COOP”) and Forbion III Management B.V. (“Forbion III”). Forbion III Coop is the record owner of (i) 4,866,449 shares of our common stock and (ii) 248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock. Forbion III, the director of Forbion III Coop, has voting and investment power over the shares held by Forbion III Coop, which are exercised through Forbion’s investment committee, consisting of H. A. Slootweg, M. A. van Osch, G. J. Mulder, H.N. Reithinger, M. Boorsma and S. J. H. van Deventer. None of the members of the investment committee have individual voting and investment power with respect to such shares, and the members of the investment committee, including H.A. Slootweg, a member of our Board, disclaim beneficial ownership of such shares except to the extent of their proportionate pecuniary interests therein. The address for Forbion III COOP and Forbion III is Gooimeer 2-35, 1411 DC Naarden, the Netherlands.
(4)
Based on information provided to us by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), orOmega Fund IV GP Manager, Ltd. (“Omega Ltd”) and Otello Stampacchia (“Stampacchia”). Consists of (i) 5,008,245 shares of our common stock held by Omega Fund and (ii) an immediately exercisable warrant held by Omega Fund to purchase 248,672 shares of our common stock, but does not include the 43,500 shares of our common stock issuable upon the exercise of options held by Stampacchia. Omega Ltd serves as the general partner of Omega GP, iswhich serves as the general partner of Omega Fund, IV, L.P., orand each of Omega GP and Omega Ltd may be deemed to own
beneficially the shares held by Omega Fund. Omega Fund IV GP Manager, Ltd., or Omega Ltd, is the general partner of Omega GP. Otello Stampacchia Richard Lim, and Anne-Mari Paster (“Paster”) are the directors of Omega Ltd. Each of Omega Fund, Omega GP, Omega Ltd Mr. Stampacchia, Mr. Lim, and Ms. Paster may be deemed to beneficially own the shares held by Omega Fund. The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Stampacchia, and the above named individualsPaster, is c/o Omega Fund Management, LLC, 888 Boylston St.,Street, Suite 1111, Boston, MA 02199.
(5)
(2)Based solely on (i) a Schedule 13G13G/A filed with the SEC on February 14, 2019, Forbion III Management B.V. is16, 2021 filed by the director of Forbion Capital Fund III Coöperatief U.A. and may be deemed to beneficially own the shares held by Forbion Capital Fund III Coöperatief U.A. The address for Forbion Capital Fund III Coöperatief U.A. and Forbion III Management B.V. is Gooimeer 2-35, 1411 DC Naarden, the Netherlands.
(3)Based on a Schedule 13G filed with the SEC on February 13, 2019, a Form 4 filed with the SEC on February 14, 2019 andRedmile Group, LLC, (ii) information provided to us by representativesRedmile Group, LLC and (iii) information otherwise available to us. Consists of Atlas Venture
Table(x) 3,993,399 shares of Contents
Associates X, L.P.our common stock and (y) 749,887 shares of our common stock issuable upon exercise of certain warrants, which, due to a beneficial ownership limitation (the “Limitation”), Atlas Venture Associates X, L.P. is the general partnermaximum number of Atlas Venture Fund X, L.P., and Atlas Venture Associates X, LLC is the general partnershares of Atlas Venture Fund X, L.P. Peter Barrett, Bruce Booth, Jean-Francois Formela, Jeff Fagnan, Chris Lynch and Ryan Moore are the membersour common stock that could be issued upon exercise of Atlas Venture Associated X, LLC and collectively make investment decisions on behalfsuch warrants (the “Redmile Shares”) as of Atlas Venture Fund X, LLC. Each of Atlas Venture Fund X, L.P., Atlas Venture Associates X, L.P., and Atlas Venture Associates X, LLC may be deemed to beneficially own the shares held by Atlas Venture Fund X, L.P. Atlas Venture Fund X, L.P. disclaims beneficial ownership of all shares except to the extent of pecuniary interest therein.June 30, 2021. The address for Atlas Venture Fund X, is 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139.
(4)Based solely on a Schedule 13G filed with the SEC on August 1, 2018, Bain Capital Life Sciences Investors, LLC, or BCI LS, is the general partners of Bain Capital Life Sciences Partners, LP, or BC LS P, which is the general partner of Bain Capital Life Sciences Fund, L.P., or BC LS. Boylston Coinvestors, LLC, or Boylston, is the general partner of BCIP Life Sciences Associates, LP, or BCIP LS. The governance, investment strategy and decision-making process with respect to investments held by BC LS and BCIP LS are directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by BC LS and BCIP LS. The address of BC LS and BCIP LS is 200 Clarendon Street, Boston, Massachusetts 02116.
(5)Based solely on a Schedule 13G filed with the SEC on February 14, 2019, the sharesRedmile Shares are owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The Redmile Shares may also be deemed beneficially owned by Jeremy C. Green isas the principal of Redmile Group, LLC. Redmile Group, LLC and Jeremy C. Green may be deemed to be the beneficial owners of such shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares,the Redmile Shares, except to the extent of its or his pecuniary interest in such shares,Redmile Shares, if any. The 4,743,286 shares of our securities reported as beneficially owned by Redmile Group, LLC represents 9.99% of the outstanding shares of our common stock as of June 30, 2021 in accordance with Section 13(d) of the Exchange Act and does not include 3,243,512 shares of our common stock that would otherwise be issuable upon exercise of certain warrants but for the Limitation. The Limitation is 9.99% of the shares of Common Stock then issued and outstanding (as determined pursuant of Section 13(d) of the Exchange Act), which percentage may be changed at Redmile Group, LLC’s election upon 61 days’ notice. The address of Redmile Group, LLC and Mr. Green is One Letterman Drive, Building D, Suite D3-300, The Presidio of San Francisco, San Francisco, California 94129.
(6)
(6)Based on a Schedule 13G filed with the SEC on January 23, 2019 and information provided to the Company, Foresite Capital Management III, LLC, or FCM III is the general partner of Foresite Capital Fund III, L.P., or FCF III, and Foresite Capital Management IV, LLC, or FCM IV, is the general partner of Foresite Capital Fund IV, L.P., or FCF IV. The managing member of FCM III and FCM IV, James Tananbaum, may be deemed to have sole power to dispose of the shares held by each of FCF III and FCF IV. Each of FCF III, FCM III, FCF IV, and FCM IV, each of its members, and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and this footnote is not an admission that FCF III, FCM III, FCF IV, or FCM IV, any of its members, or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose. The address of FCF III, FCM III, FCF IV, FCM IV, and Mr. Tananbaum is c/o Foresite Capital Management, 600 Montgomery Street, Suite 4500, San Francisco, California 94111.
(7)Based solely on a Schedule 13G filed with the SEC on March 26, 2019, BVF Partners OS Ltd., or Partners OS, the general partnerFebruary 16, 2021 by T. Rowe Price Associates, Inc. (“Price Associates”). Price Associates beneficially owns 2,625,691 shares of Biotechnology Value Trading Fund OS LP, or Trading Fund OS, may be deemed to beneficially own the shares held by Trading Fund OS. BVF Partners L.P., or Partners, the general partner of Biotechnology Value Fund, L.P., or BVF, and Biotechnology Value Fund II, L.P., or BVF2, the investment manager of Trading Fund OS, and the sole member of Partner OS, may be deemed to beneficially own the shares held by BVF, BVF2, Trading Fund OS, and certain Partners managed accounts, or the Partners Managed Accounts. BVF Inc., the general partner of Partners, may be deemed to beneficially own the shares
Table of Contents
beneficially owned by Partners. Mark N. Lampert, the director and officer of BVF, Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. The foregoing should not be construedour common stock in and of itselfits capacity as an admission by anyinvestment adviser. Price Associates has sole voting and sole dispositive power over 504,564 and 2,625,691 shares of the foregoing entities or individuals as to beneficial ownershipour common stock, respectively. The Address of any shares owned by another beneficial owner. Partners OS disclaims beneficial ownership of the shares beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts. The address for each of BVF, BVF2, Partners, BVF Inc., and Mr. LampertPrice Associates is 44 Montgomery St., 40th Floor, San Francisco, California 94104. The address for each of Trading Fund OS and Partners OS is PO Box 309 Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
(8)- 100 E. Pratt Street, Baltimore, Maryland 21202.
(7)
Consists of (i) 2,412,1181,255,297 shares of our common stock and (ii) 213,159375,021 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.2021.
(8)
(9)Consists of (i) 1,442,2971,706,629 shares of our common stock and (ii) 84,541669,417 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.2021.
(9)
(10)Consists of 112,102(i) 1,000 shares of our common stock held by Ms. Pirzkall’s husband over which Ms. Pirzkall may be deemed to be the beneficial owner and (ii) 81,250 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.2021.
(10)
(11)Consists entirely of (i) 1,119,024 shares of our common stock and (ii) 104,787158,710 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.2021.
(11)
(12)Consists entirely of (i) 3,79657,000 shares of common stock underlying options that are exercisable within 60 days of June 30, 20192021.
(12)
Consists entirely of 12,374 shares of common stock underlying options that are exercisable within 60 days of June 30, 2021.
(13)
Consists of (i) 43,500 shares of common stock underlying options held by Jason Rhodes that are exercisable within 60 days of June 30, 2021 and (ii) 3,822,3133,229,912 shares of common stock held by affiliates of Atlas Ventures. Mr. Rhodes is a partner at Atlas Ventures. Mr. Rhodes disclaims beneficial ownership of all shares held of record by affiliates of Atlas Ventures.
(14)
(13)Consists of (i) 3,7966,667 shares of our common stock and (ii) 74,631 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019 and (ii) 4,970,1212021.
(15)
Consists of (i) 43,500 shares of common stock underlying options held by Sander Slootweg that are exercisable within 60 days of June 30, 2021 and (ii) 5,115,121 securities held by affiliates of Forbion Capital Partners.Partners (see note (3)). Mr. Slootweg is a managing partner of Forbion Capital Partners. Mr. Slootweg disclaims beneficial ownership of all sharessecurities held of record by affiliates of Forbion Capital Partners.
(16)
Consists of (i) 3,79643,500 shares of common stock underlying options held by Otello Stampacchia that are exercisable within 60 days of June 30, 20192021 and (ii) 5,103,455 shares of common stock5,256,917 securities held by affiliates of Omega Fund Management.Management (see note (4)). Dr. Stampacchia is a managing member of Omega Fund Management. Dr. Stampacchia disclaims beneficial ownership of all sharessecurities held of record by affiliates of Omega Fund Management.
(17)
(15)Consists entirely of 159,00665,250 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.2021.
(18)
(16)Consists of 7,593(i) 17,116,002 shares of our common stock, and (ii) 2,840,685 shares of common stock underlying options and securities that are exercisable within 60 days of June 30, 2019.
(17)Consists of (i) 6,667 shares of our common stock and (ii) 17,466 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.
(18)Consists of 7,593 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.
(19)Consists of (i) 18,962,955 shares of common stock and (ii) 1,119,887 shares of common stock underlying options that are exercisable within 60 days of June 30, 2019.2021.
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Related Party Transactions Policy
Our Board has adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the prior review and ratification of
ourthe Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons in which the amount involved exceeds $120,000 and such person would have a direct or indirect material interest must first be presented to
ourthe Audit Committee for review, consideration and approval. In approving or rejecting any such proposal,
ourthe Audit Committee is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related
person'sperson’s interest in the transaction.
During the fiscal year ended March 31,
2019,2021, we were not a party to any transactions or series of similar transactions, in which:
•
the amounts involved exceeded or will exceed $120,000; and
•
•any of the directors, executive officers or holders of more than 5% of our voting equity, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.
Compensation arrangements for our directors and named executive officers are described elsewhere in this Proxy Statement.
Table of Contents
TABLE OF CONTENTS
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than 10% of a registered class of our equity securities to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons are required by regulation of the SEC to furnish us with copies of all Section 16(a) forms they file. Based solely on our review of the copies of such forms or written representations from certain reporting persons received by us with respect to the fiscal year ended March 31, 2019, our directors, officers and stockholders who own more than 10% of a registered class of our equity securities complied with all applicable filing requirements during the fiscal year ended March 31, 2019.
Availability of Certain Documents
A copy of our Annual Report on Form 10-K for the fiscal year ended March 31,
20192021 has been posted along with this Proxy Statement at www.envisionreports.com/REPL or www.replimune.com under
"Investors and Media"“Investors & Media” at
"Financials“Financials & Filings.
"” We will mail without charge, upon written request, a copy of our Annual Report on Form 10-K for the fiscal year ended March 31,
20192021, including financial statements and schedules thereto, but excluding
exhibits. A reasonable fee will be charged for copied of exhibits. Please send a written request to Investor Relations at:
Replimune Group, Inc.18 Commerce Way500 Unicorn ParkWoburn, MA 01801Attention: Investor Relations You may also find a copy of this Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended March 31,
20192021 (with exhibits) on the SEC website at www.sec.gov.
Stockholders Sharing an Address / Household
Householding The SEC has adopted rules that permit companies and intermediaries (such as banks and brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
Only one copy of our Annual Report on Form 10-K for the fiscal year ended March 31,
20192021 and this Proxy Statement is being delivered to multiple stockholders sharing an address, unless we have received contrary instructions from one or more of the stockholders.
We will undertake to deliver promptly, upon written or oral request, a separate copy to a stockholder at a shared address to which a single copy of the Annual Report on Form 10-K for the fiscal year ended March 31,
20192021 and this Proxy Statement was delivered. To receive a separate copy of our Annual Report on Form 10-K for the fiscal year ended March 31,
20192021 or Proxy Statement, or to receive separate copies in the future, or if two stockholders sharing an address have received two copies of any of these documents and desire to only receive one, you may write to Investor Relations at Replimune Group, Inc. at our principal executive offices at
18 Commerce Way,500 Unicorn Park, Woburn, MA 01801 or call Investor Relations at +1
(781) 222-9600.(339) 970-2843.
Stockholder Proposals and Nominations
Requirements for Stockholder Proposals to be Considered for Inclusion in our Proxy Materials. Under Rule 14a-8 of the Exchange Act, to submit a proposal for inclusion in our Proxy Statement for the 20202021 Annual Meeting of Stockholders, stockholder proposals must be received no later than close of business on March 31, 2020,2021, by our Secretary at our principal executive offices at 18 Commerce Way,500 Unicorn Park, Woburn, MA 01801. Requirements for Stockholder to bring Business and Nominations Before an Annual Meeting.Meeting of Stockholder. Our bylaws provide that, for stockholder nominations to the Board or other business to be considered at the 20202022 Annual Meeting of Stockholders, the stockholder must have given timely notice thereof in writing to the Secretary at Replimune Group, Inc., 18 Commerce Way,500 Unicorn Park, Woburn, MA 01801 between May 7, 202011, 2022 and June 6, 202010, 2022 (assuming the date of our 20202022 Annual Meeting of Stockholders is not so advanced or delayed as described in our bylaws). To be timely for the 20202022 Annual Meeting of Stockholders, the stockholder'sstockholder’s notice must be delivered to or mailed and received by us not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the anniversary date of the previous year'syear’s annual meeting, except that if the annual meeting is scheduled more than 30 days before or 60 days after such anniversary date, we must receive the notice not later than the close of business on the 10th day following the day on which we first provide notice or public disclosure of the date of the meeting.
Such notice must provide the information required by Section 2.12 of
theour bylaws with respect to each nomination or matter the stockholder proposes to bring before the
20202022 Annual
Meeting.
TableMeeting of Contents
Stockholders.
As of the date of this Proxy Statement, the Board does not intend to present any matters other than those described herein at the
2019 Annual Meeting and is unaware of any matters to be presented by other parties. If other matters are properly brought before the meeting for action by the stockholders, proxies will be voted in accordance with the recommendation of the Board or, in the absence of such a recommendation, in accordance with the judgment of the proxy holder.
| | |
| | By Order of the Board of Directors |
|
|
/s/ ROBERT COFFIN
Robert Coffin, Ph.D.
President and Chief Executive Officer
August 9, 2019 |
Table of Contents
Appendix A
CERTIFICATE OF AMENDMENT
TO
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
REPLIMUNE GROUP, INC.
(Pursuant to Section 242 of the
General Corporation Law of the State of Delaware)
Replimune Group, Inc., a corporation organized and existing under and by virtue of the provision of the General Corporation Law of the State of Delaware (the "Corporation"),
DOES HEREBY CERTIFY:
1. That the Board of Directors duly adopted resolutions proposing to amend the Third Amended and Restated Certificate of Incorporation of the Corporation (the "
/s/ Certificate of IncorporationPhilip A"), declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolutions setting forth the proposed amendment are substantially as follows:stley-SRESOLVEDparke
, that the Certificate of Incorporation is hereby amended by amending and restating Article Eleven thereof as follows:Philip Astley-Sparke"Unless the Corporation, as authorized by the Board of Directors, consents in writing to the selection of one or more alternative forums, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for a stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation's stockholders, (iii) any action asserting a claim against the Corporation arising pursuant to any provision of the DGCL or this Restated Certificate or the Corporation's by-laws or (iv) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine; except for, as to each of (i) through (iv) above, any claim (A) as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within ten (10) days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than such court, or (C) for which such court does not have subject matter jurisdiction. Notwithstanding the foregoing, nothing in this Article Eleven shall preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the U.S. Securities Act of 1933, as amended, or the U.S. Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, or otherwise limit the rights of any stockholder (including a beneficial owner) to bring any claim under such laws, rules or regulations in any United States federal district court of competent jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation (including, without limitation, shares of Common Stock) shall, and shall be deemed to, have notice of and to have consented to the provisions of this Article Eleven."
[Chief Executive Officer
July 22, 2021
(The remainder of this page
intentionallyhas been left
blank]
blank intentionally.)
Table of Contents
IN WITNESS WHEREOF, the undersigned has caused this Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Corporation to be duly executed on behalf of the Corporation on September , 2019.
| | | | | | |
| | Replimune Group, Inc. |
|
|
By: |
|
37
|
| | | | Name: | | Philip Astley-Sparke |
| | | | Title: | | Secretary |
![[MISSING IMAGE: tm2122609d-px_pg01proxybw.jpg]](https://files.docoh.com/DEF 14A/0001104659-21-094885/tm2122609d-px_pg01proxybw.jpg)
MMMMMMMMMMMM MMMMMMMMMMMMMMM C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000004 ENDORSEMENT_LINE______________ SACKPACK_____________ Your vote matters – here’s how to vote! You may vote online or by phone instead of mailing this card. Votes submitted electronically must be MR A SAMPLE DESIGNATION (IF ANY) ADD01 - Robert Coffin, Ph.D. 02 - Hyam Levitsky, M.D. 03 - Dieter WeinandFor Withhold For Withhold For Withhold3 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 received 1:00 am, (EST), on September, 03, 2019 Online GIof ntoo welwewct.rinovneicstvoortviontge,.com/REPL delete QR code and control # or scan the QR code — login details are located in the shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Sign up for electronic delivery at www.investorvote.com/REPL UsingB VUsing a black ink pen, mark your votes with an X as shown in this example. Pleaseexample.Please do not write outside the designated areas. q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q areas.03HNDB++ 1. ElectionProposals — The Board of Directors: For Withhold For Withhold For Withhold 01 - Philip Astley-Sparke 02 - Kapil Dhingra 03 - Joseph Slattery ForAgainst Abstain ForAgainst Abstain 2. To amend the Certificate of IncorporationDirectors of Replimune Group, Inc. 3.recommends a vote FOR all the nominees listed A and FOR Proposal 2.2. To ratify the appointmentselection of PricewaterhouseCoopers LLP as independenttheindependent registered public accounting firm for ReplimuneGroup, Inc. for the fiscal year endedending March 31, 2020. Please2022.1. Election of Directors:For Against AbstainPlease sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Dategivefull title.Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. MMMMMMM C 1234567890 J N T 2 5 3 2 5 MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + 3 2 B V 4 033NBB MMMMMMMMM Bbox.B Authorized Signatures — This section must be completed for your vote to count. Please date and sign below. A Proposals — The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2 and 3. 2019 Annual Meeting Proxy Card1234 5678 9012 345
2019 Annual Meeting Admission Ticket 2019below.q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.q2021 Annual Meeting of Replimune Group, Inc. Stockholders Wednesday,Proxy CardYou may vote online or by phone instead of mailing this card.OnlineGo to www.envisionreports.com/REPLor scan the QR code — login details arelocated in the shaded bar below.Save paper, time and money!Sign up for electronic delivery atwww.envisionreports.com/REPLPhoneCall toll free 1-800-652-VOTE (8683) withinthe USA, US territories and CanadaYour vote matters – here’s how to vote!
![[MISSING IMAGE: tm2122609d-px_pg02proxybw.jpg]](https://files.docoh.com/DEF 14A/0001104659-21-094885/tm2122609d-px_pg02proxybw.jpg)
Small steps make an impact.Help the environment by consenting to receive electronicdelivery, sign up at www.envisionreports.com/REPLNotice of 2021 Annual Meeting of StockholdersProxy Solicited by Board of Directors for Annual Meeting — September 4, 2019,8, 2021The undersigned stockholder(s) of Replimune Group, Inc. hereby appoint(s) Philip Astley-Sparke and Jean Franchi, or either of them, as proxies, each withthe power to appoint his or her substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this proxy card, allof the shares of common stock of Replimune Group, Inc. that the undersigned stockholder(s) is/are entitled to vote at the 2021 Annual Meeting ofStockholders of Replimune Group, Inc. (the “Annual Meeting”) to be held at 2:00 PM, Eastern Time Offices of Morgan, Lewis & Bockius LLP One Federal Street, Boston, MA 02110 Upon arrival, please present this admission ticketEDT on September 8, 2021, via live webcast atmeetings.computershare.com/MACDYTJ, and photo identification atany adjournment, continuation or postponement thereof.Such proxies are authorized to vote in their full discretion (i) FOR the registration desk. If you plan to attend the annual meeting in person, please bring this admission ticket with you. This ticket admits the stockholder. All meeting attendees must present valid government-issued identification. For your safety, all personal belongings or effects including bags, purses, and briefcases are subject to inspection. With the exception of purses and notepads, no personal items such as briefcases or bags,election of any type,person to the Board of Directors of Replimune Group, Inc. (the “Board”)if any nominee named herein becomes unable to serve or for good cause will not serve, (ii) on any matter that the Board did not know would be presentedat the Annual Meeting within a reasonable time prior to conducting this proxy solicitation, and (iii) on such other business as may properly be carried into the meeting area. The use of photographic and recording devices is prohibitedbrought beforethe Annual Meeting or any adjournment, continuation or postponement thereof.This proxy, when executed, will be voted in the building. Cell phone usemanner directed herein by the undersigned stockholder(s).If no such direction is permitted only outdoors. The meeting location is accessible to disabled persons. Space is limited, and stockholdersindicated, this proxy will be admittedvoted in accordance with the Board’s recommendation.(Items to be voted appear on a first-come, first-served basis. reverse side)Replimune Group, Inc.q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.qChange of Address — Please print new address below. Comments — Please print your comments below.C Non-Voting Items++Important notice regarding the Internet availability of proxy materials for the Annual Meeting of Shareholders. TheStockholders.The material is available at: www.investorvote.com/REPL q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q + Notice of 2019 Annual Meeting of Stockholders Proxy Solicited by Board of Directors for Annual Meeting — September 4, 2019 Robert Coffin and Philip Astley-Sparke, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at thewww.envisionreports.com/REPLThe 2021 Annual Meeting of Stockholders of Replimune Group, Inc. towill be held on Wednesday, September 4, 2019 or8, 2021 at any postponement or adjournment thereof. Shares represented by2:00 PM Eastern Time via live webcastat meetings.computershare.com/MACDYTJ.To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this proxy will be voted by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR the election of the Board of Directors, FOR item 2, and FOR item 3. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side) Change of Address — Please print new address below. Comments — Please print your comments below. + C Non-Voting Items Replimune Group, Inc. Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.investorvote.com/REPL
MMMMMMMMMMMM Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q + 1. Election of Directors: For Withhold For Withhold For Withhold 01 - Philip Astley-Sparke 02 - Kapil Dhingra 03 - Joseph Slattery ForAgainst Abstain ForAgainst Abstain 2. To amend the Certificate of Incorporation of Replimune Group, Inc. 3. To ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ended March 31, 2020. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. + 1 U P X 4 2 5 3 2 5 033NCB MMMMMMMMM B Authorized Signatures — This section must be completed for your vote to count. Please date and sign below. A Proposals — The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2 and 3. 2019 Annual Meeting Proxy Card
Important notice regarding the Internet availability of proxy materials for the Annual Meeting of Shareholders. The material is available at: www.investorvote.com/REPL q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Notice of 2019 Annual Meeting of Stockholders Proxy Solicited by Board of Directors for Annual Meeting — September 4, 2019 Robert Coffin and Philip Astley-Sparke, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of Replimune Group, Inc. to be held on September 4, 2019 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR the election of the Board of Directors, FOR item 2, and FOR item 3. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side) Replimune Group, Inc.
![[MISSING IMAGE: lg_replimune-4c.jpg]](https://files.docoh.com/DEF 14A/0001104659-21-094885/lg_replimune-4c.jpg)
